Date,Symbol,Headline,Source11-Nov-20,NKTR-US,DJ Press Release: Nektar Therapeutics Presents New -3-,DJGM11-Nov-20,NKTR-US,DJ Press Release: Nektar Therapeutics Presents New -2-,DJGM11-Nov-20,NKTR-US,DJ Press Release: Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting,DJGM11-Nov-20,NKTR-US,Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting,PRN9-Nov-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society of Immunotherapy of Cancer Meeting for 11-November-2020 4:15 PM ET,FCSTEV9-Nov-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society of Immunotherapy of Cancer Meeting - Abstract #355 for 11-November-2020 5:15 PM ET,FCSTEV9-Nov-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society of Immunotherapy of Cancer Meeting - Abstract 451 for 11-November-2020 5:15 PM ET,FCSTEV9-Nov-20,NKTR-US,DJ Press Release: Nektar Therapeutics to Host -2-,DJGM9-Nov-20,NKTR-US,DJ Press Release: Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting,DJGM9-Nov-20,NKTR-US,Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting,PRN6-Nov-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society of Immunotherapy of Cancer Meeting - Abstract #420 for 11-November-2020 1:30 PM ET,FCSTEV6-Nov-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society of Immunotherapy of Cancer Meeting - Abstract #368 for 11-November-2020 11:15 AM ET,FCSTEV5-Nov-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society of Immunotherapy of Cancer Meeting - BEMPEG - CD122 for 9-November-2020,FCSTEV5-Nov-20,NKTR-US,DJ Press Release: Nektar Therapeutics Reports Third -3-,DJGM5-Nov-20,NKTR-US,DJ Press Release: Nektar Therapeutics Reports Third -2-,DJGM5-Nov-20,NKTR-US,DJ Press Release: Nektar Therapeutics Reports Third Quarter 2020 Financial Results,DJGM5-Nov-20,NKTR-US,Nektar Therapeutics Reports Third Quarter 2020 Financial Results,PRN5-Nov-20,NKTR-US,Nektar Therapeutics to Host Earnings Call,NEWS_ACW4-Nov-20,NKTR-US,"DJ Press Release: New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress",DJGM4-Nov-20,NKTR-US,"New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress",PRN29-Oct-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Business Update Call for 4-November-2020 4:15 PM ET,FCSTEV29-Oct-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American College of Rheumatology Congress - Abstract: 1824 for 9-November-2020 9:00 AM ET,FCSTEV29-Oct-20,NKTR-US,DJ Press Release: Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) Congress,DJGM29-Oct-20,NKTR-US,Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) Congress,PRN28-Oct-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2020 Earnings Call for 5-November-2020 5:00 PM ET,FCSTEV28-Oct-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2020 Earnings Release for 5-November-2020 4:15 PM ET,FCSTEV28-Oct-20,NKTR-US,"DJ Press Release: Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets",DJGM28-Oct-20,NKTR-US,"Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets",PRN27-Oct-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Bempegaldesleukin Phase 1B Clinical Study Results Call for 27-October-2020 8:30 AM ET,FCSTEV27-Oct-20,NKTR-US,DJ Press Release: Nektar Therapeutics Announces -2-,DJGM27-Oct-20,NKTR-US,DJ Press Release: Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19,DJGM27-Oct-20,NKTR-US,Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19,PRN12-Aug-20,NKTR-US,DJ Press Release: Vaccibody AS and Nektar -2-,DJGM12-Aug-20,NKTR-US,"DJ Press Release: Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck",DJGM12-Aug-20,NKTR-US,"Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck",PRN6-Aug-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Cambridge Healthtech Institute Immuno-Oncology Virtual Summit for 8-October-2020 9:40 AM ET,FCSTEV6-Aug-20,NKTR-US,DJ Press Release: Nektar Therapeutics Reports Second Quarter 2020 Financial Results,DJGM6-Aug-20,NKTR-US,DJ Press Release: Nektar Therapeutics Reports Second -2-,DJGM6-Aug-20,NKTR-US,Nektar Therapeutics Reports Second Quarter 2020 Financial Results,PRN28-Jul-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2020 Earnings Call for 6-August-2020 5:00 PM ET,FCSTEV28-Jul-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2020 Earnings Release for 6-August-2020 4:15 PM ET,FCSTEV28-Jul-20,NKTR-US,"DJ Press Release: Nektar to Announce Financial Results for the Second Quarter 2020 on Thursday, August 6, 2020, After Close of U.S.-Based Financial Markets",DJGM28-Jul-20,NKTR-US,"Nektar to Announce Financial Results for the Second Quarter 2020 on Thursday, August 6, 2020, After Close of U.S.-Based Financial Markets",PRN4-Jun-20,NKTR-US,"DJ Press Release: Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)",DJGM4-Jun-20,NKTR-US,"Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)",PRN29-May-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules EULAR E-Congress - Abstract No - THU0054 for 4-June-2020,FCSTEV29-May-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules EULAR E-Congress for 5-June-2020 11:00 AM ET,FCSTEV29-May-20,NKTR-US,DJ Press Release: Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020),DJGM29-May-20,NKTR-US,Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020),PRN22-May-20,NKTR-US,DJ Press Release: Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal,DJGM22-May-20,NKTR-US,Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal,PRN7-May-20,NKTR-US,DJ Press Release: Nektar Therapeutics Reports First -3-,DJGM7-May-20,NKTR-US,DJ Press Release: Nektar Therapeutics Reports First -2-,DJGM7-May-20,NKTR-US,DJ Press Release: Nektar Therapeutics Reports First Quarter 2020 Financial Results,DJGM7-May-20,NKTR-US,Nektar Therapeutics Reports First Quarter 2020 Financial Results,PRN4-May-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Annual General Meeting for 17-June-2020 5:00 PM ET,FCSTEV28-Apr-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2020 Earnings Call for 7-May-2020 5:00 PM ET,FCSTEV28-Apr-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2020 Earnings Release for 7-May-2020 4:15 PM ET,FCSTEV28-Apr-20,NKTR-US,"DJ Press Release: Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets",DJGM28-Apr-20,NKTR-US,"Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets",PRN3-Mar-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society of Toxicology Meeting - Leung for 18-March-2020 1:45 PM ET,FCSTEV3-Mar-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Cowen and Company Health Care Conference for 3-March-2020 9:20 AM ET,FCSTEV2-Mar-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society of Toxicology Meeting - Gunther for 18-March-2020 1:45 PM ET,FCSTEV28-Feb-20,NKTR-US,Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference,PRN28-Feb-20,NKTR-US,"Nektar Therapeutics(NKTR-US) Schedules Society of Toxicology Meeting - Leung, S., et al for 18-March-2020 1:45 PM ET",FCSTEV28-Feb-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Chemical Society National Meeting - NKTR-262: Discovery of a novel TLR 7/8 agonist prodrug  for 24-March-2020 10:10 AM ET,FCSTEV27-Feb-20,NKTR-US,DJ Press Release: Nektar Therapeutics Reports Fourth -3-,DJGM27-Feb-20,NKTR-US,DJ Press Release: Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results,DJGM27-Feb-20,NKTR-US,DJ Press Release: Nektar Therapeutics Reports Fourth -2-,DJGM27-Feb-20,NKTR-US,Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results,PRN18-Feb-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2019 Earnings Release for 27-February-2020 4:15 PM ET,FCSTEV18-Feb-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2019 Earnings Call for 27-February-2020 5:00 PM ET,FCSTEV18-Feb-20,NKTR-US,"DJ Press Release: Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets",DJGM18-Feb-20,NKTR-US,"Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets",PRN3-Feb-20,NKTR-US,DJ Press Release: Nektar Therapeutics Announces -2-,DJGM3-Feb-20,NKTR-US,"DJ Press Release: Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications",DJGM3-Feb-20,NKTR-US,"Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications",PRN29-Jan-20,NKTR-US,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics  - NKTR,PMZ24-Jan-20,NKTR-US,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics  - NKTR,PRN21-Jan-20,NKTR-US,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR,PMZ14-Jan-20,NKTR-US,DJ Press Release: Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol,DJGM14-Jan-20,NKTR-US,Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol,PRN13-Jan-20,NKTR-US,"Thinking about buying stock in Bilibili, Microsoft, Nio, Nektar Therapeutics, or NVIDIA?",PRN10-Jan-20,NKTR-US,Shareholder Alert: Robbins LLP Reminds Investors Nektar Therapeutics (NKTR) Sued for Misleading Shareholders,BW10-Jan-20,NKTR-US,DJ Press Release: Nektar Therapeutics and -4-,DJGM10-Jan-20,NKTR-US,DJ Press Release: Nektar Therapeutics and -3-,DJGM10-Jan-20,NKTR-US,DJ Press Release: Nektar Therapeutics and -2-,DJGM10-Jan-20,NKTR-US,DJ Press Release: Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab),DJGM10-Jan-20,NKTR-US,DJ Press Release: Nektar Therapeutics and -5-,DJGM10-Jan-20,NKTR-US,Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab),BW7-Jan-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules JP Morgan Health Care Conference for 13-January-2020 5:30 PM ET,FCSTEV7-Jan-20,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules JP Morgan Health Care Conference - Q&A Session for 13-January-2020 6:00 PM ET,FCSTEV7-Jan-20,NKTR-US,"DJ Press Release: Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",DJGM7-Jan-20,NKTR-US,"Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN17-Dec-19,NKTR-US,"DJ Press Release: Nektar Therapeutics Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.",DJGM17-Dec-19,NKTR-US,"Nektar Therapeutics Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.",PRN9-Dec-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Hematology Meeting - Abstract 4398 for 9-December-2019 6:00 PM ET,FCSTEV9-Dec-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Hematology Meeting - Abstract 4459 for 9-December-2019 6:00 PM ET,FCSTEV9-Dec-19,NKTR-US,"DJ Press Release: Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting",DJGM9-Dec-19,NKTR-US,DJ Press Release: Nektar Therapeutics Announces -2-,DJGM9-Dec-19,NKTR-US,"Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting",PRN8-Dec-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Hematology Meeting - Abstract 2866 for 8-December-2019 6:00 PM ET,FCSTEV3-Dec-19,NKTR-US,DJ Press Release: Nektar Appoints John Northcott as Chief Commercial Officer,DJGM3-Dec-19,NKTR-US,Nektar Appoints John Northcott as Chief Commercial Officer,PRN13-Nov-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules The Promise of Interleukin-2 Therapy Meeting for 15-November-2019 10:30 AM ET,FCSTEV13-Nov-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Jefferies London Health Care Conference for 20-November-2019 11:00 AM ET,FCSTEV13-Nov-19,NKTR-US,DJ Press Release: Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference,DJGM13-Nov-19,NKTR-US,Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference,PRN12-Nov-19,NKTR-US,Biotechs Seek Advancements in the Immuno-Oncology Field for Childhood Brain Tumors,PRN10-Nov-19,NKTR-US,DJ Press Release: Nektar Therapeutics Presents Data -2-,DJGM10-Nov-19,NKTR-US,"DJ Press Release: Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology",DJGM10-Nov-19,NKTR-US,"Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology",PRN9-Nov-19,NKTR-US,Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting,PRN7-Nov-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Hematology Meeting - Session: 625 for 8-December-2019 6:00 PM ET,FCSTEV7-Nov-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules PEG Europe Conference - Presentation: NKTR-255 for 21-November-2019 6:15 AM ET,FCSTEV7-Nov-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Poster: NKTR-255 for 8-November-2019 7:00 AM ET,FCSTEV7-Nov-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American College of Rheumatology Meeting for 10-November-2019 9:00 AM ET,FCSTEV7-Nov-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Hematology Meeting - Session: 652 for 9-December-2019 6:00 PM ET,FCSTEV7-Nov-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules PEG Europe Conference for 19-November-2019 12:30 PM ET,FCSTEV7-Nov-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules The Promise of Interleukin-2 Therapy Meeting for 15-November-2019 10:30 AM ET,FCSTEV7-Nov-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Melanoma Bridge Conference for 7-December-2019 6:00 AM ET,FCSTEV7-Nov-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Hematology Meeting - Session: 704 for 9-December-2019 6:00 PM ET,FCSTEV7-Nov-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules The Promise of Interleukin-2 Therapy Meeting for 15-November-2019 8:00 AM ET,FCSTEV6-Nov-19,NKTR-US,DJ Press Release: Nektar Therapeutics Reports -3-,DJGM6-Nov-19,NKTR-US,DJ Press Release: Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019,DJGM6-Nov-19,NKTR-US,DJ Press Release: Nektar Therapeutics Reports -2-,DJGM6-Nov-19,NKTR-US,Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019,PRN4-Nov-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting for 10-November-2019 9:00 AM ET,FCSTEV1-Nov-19,NKTR-US,DJ Press Release: Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting,DJGM1-Nov-19,NKTR-US,Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting,PRN31-Oct-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2019 Earnings Release for 6-November-2019 4:03 PM ET,FCSTEV31-Oct-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2019 Earnings Call for 6-November-2019 5:00 PM ET,FCSTEV30-Oct-19,NKTR-US,"DJ Press Release: Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets",DJGM30-Oct-19,NKTR-US,"Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets",PRN29-Oct-19,NKTR-US,Clinical Trials in Gene Sequencing Reveal Novel Mutations Aiding in New Treatments for Acute Myeloid Leukemia,PRN16-Oct-19,NKTR-US,"FINAL DEADLINE APPROACHING: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics ",BW16-Oct-19,NKTR-US,"Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma",PRN15-Oct-19,NKTR-US,"DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics, Inc. (NASDAQ: NKTR) and Encourages Nektar Investors to Contact the Firm",BW15-Oct-19,NKTR-US,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR,PMZ15-Oct-19,NKTR-US,"INVESTOR DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics ",NEWS_ACW10-Oct-19,NKTR-US,"SHAREHOLDER ALERT:  Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics ",PMZ9-Oct-19,NKTR-US,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NetApp, SAExploration, Nektar Therapeutics, and Valaris and Encourages Investors to Contact the Firm",PMZ7-Oct-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P623 for 8-November-2019 7:00 AM ET,FCSTEV7-Oct-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract: O35 for 9-November-2019 5:15 PM ET,FCSTEV7-Oct-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P619 for 8-November-2019 7:00 AM ET,FCSTEV7-Oct-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P387 for 8-November-2019 7:00 AM ET,FCSTEV7-Oct-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P622 for 9-November-2019 7:00 AM ET,FCSTEV7-Oct-19,NKTR-US,Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis,PRN4-Oct-19,NKTR-US,"KESSLER TOPAZ MELTZER & CHECK, LLP - DEADLINE REMINDER FOR NEKTAR THERAPEUTICS INVESTORS",NEWS_ACW3-Oct-19,NKTR-US,Zhang Investor Law Reminds Investors of October 18 Deadline in Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR,PMZ2-Oct-19,NKTR-US,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NetApp, SAExploration, Nektar Therapeutics, and Valaris and Encourages Investors to Contact the Firm",PMZ2-Oct-19,NKTR-US,Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics,PMZ2-Oct-19,NKTR-US,"INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in ERI, NKTR, and GVA of Filing Deadlines",PMZ2-Oct-19,NKTR-US,Nektar Therapeutics Announces Five Abstracts Accepted for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting,PRN1-Oct-19,NKTR-US,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR,PMZ1-Oct-19,NKTR-US,"Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors",PMZ1-Oct-19,NKTR-US,Nektar Announces Key Executive Promotions,PRN27-Sep-19,NKTR-US,"ROSEN, A TOP RANKED LAW FIRM, Reminds Nektar Therapeutics Investors of Important October 18th Deadline in Securities Class Action - NKTR",PMZ26-Sep-19,NKTR-US,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics - NKTR",NEWS_ACW26-Sep-19,NKTR-US,Las Vegas Sands Set to Join S&P 500; Nektar Therapeutics to Join S&P MidCap 400; The Pennant Group to Join S&P SmallCap 600,PRN26-Sep-19,NKTR-US,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR,PRN26-Sep-19,NKTR-US,Zhang Investor Law Reminds Investors of October 18 Deadline in Securities Class Action Lawsuit Against Nektar Therapeutics- NKTR,PMZ26-Sep-19,NKTR-US,Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference,PRN25-Sep-19,NKTR-US,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nektar Therapeutics, Valaris, Sarepta Therapeutics, and Canada Goose and Encourages Investors to Contact the Firm",PMZ24-Sep-19,NKTR-US,"INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in CARB, NKTR, and GVA of Filing Deadlines",PMZ24-Sep-19,NKTR-US,"INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",PMZ23-Sep-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference - Abstract #A001 for 26-September-2019 12:30 PM ET,FCSTEV23-Sep-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference - Abstract #A001 for 26-September-2019 7:00 AM ET,FCSTEV23-Sep-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference for 26-September-2019 8:30 AM ET,FCSTEV23-Sep-19,NKTR-US,"Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors",PMZ23-Sep-19,NKTR-US,Nektar Therapeutics Announces Abstract Accepted for Presentation at the 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference,PRN23-Sep-19,NKTR-US,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR,PMZ20-Sep-19,NKTR-US,"Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Class Action Reminder - Bronstein, Gewirtz & Grossman, LLC",PMZ20-Sep-19,NKTR-US,Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics,PMZ18-Sep-19,NKTR-US,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NetApp, SAExploration, Nektar Therapeutics, and Valaris and Encourages Investors to Contact the Firm",PMZ17-Sep-19,NKTR-US,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR,PMZ17-Sep-19,NKTR-US,"Kessler Topaz Meltzer & Check, LLP Reminds Nektar Therapeutics Investors of Important Deadline in Securities Fraud Class Action Lawsuit",PMZ12-Sep-19,NKTR-US,"ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Nektar Therapeutics Investors of Important October 18th Deadline in Securities Class Action - NKTR",PMZ12-Sep-19,NKTR-US,NKTR CLASS ACTION ALERT: Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Lawsuit Against Nektar Therapeutics,PRN11-Sep-19,NKTR-US,"Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors",PMZ10-Sep-19,NKTR-US,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nektar Therapeutics, Valaris, Burford, and Canada Goose and Encourages Investors to Contact the Firm",PMZ6-Sep-19,NKTR-US,"KESSLER TOPAZ MELTZER & CHECK, LLP - Reminds Investors of Securities Fraud Class Action Lawsuit Against NEKTAR THERAPEUTICS - NKTR",PMZ6-Sep-19,NKTR-US,"Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Class Action Update - Bronstein, Gewirtz & Grossman, LLC",PMZ4-Sep-19,NKTR-US,"Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics ",BW4-Sep-19,NKTR-US,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR,PMZ3-Sep-19,NKTR-US,"Kessler Topaz Meltzer & Check, LLP:  Securities Fraud Class Action Filed Against Nektar Therapeutics - NKTR",PRN30-Aug-19,NKTR-US,"Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against Nektar Therapeutics",PMZ30-Aug-19,NKTR-US,"ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR",PMZ30-Aug-19,NKTR-US,"LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm",PRN27-Aug-19,NKTR-US,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Granite Construction, Pluralsight, SAExploration, and Nektar and Encourages Investors to Contact the Firm",PMZ26-Aug-19,NKTR-US,Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics,BW23-Aug-19,NKTR-US,"INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: October 18, 2019",PMZ22-Aug-19,NKTR-US,Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR),PMZ21-Aug-19,NKTR-US,"IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",BW21-Aug-19,NKTR-US,"NEKTAR THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District for the Northern District of California against Nektar Therapeutics, Inc.",PMZ20-Aug-19,NKTR-US,"Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics, Inc. (NASDAQ: NKTR) and Encourages Nektar Investors to Contact the Firm",PRN19-Aug-19,NKTR-US,Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of Nektar Therapeutics Investors (NKTR),BW15-Aug-19,NKTR-US,"Bragar Eagel & Squire, P.C. is Investigating Nektar Therapeutics, Inc. (NASDAQ: NKTR) on Behalf of Stockholders and Encourages Nektar Investors to Contact the Firm",PRN10-Aug-19,NKTR-US,"INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",BW9-Aug-19,NKTR-US,Glancy Prongay & Murray LLP Announces Investigation on Behalf of Nektar Therapeutics Investors,BW9-Aug-19,NKTR-US,INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Nektar Therapeutics Investors,BW8-Aug-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules CAR-TCR Summit for 11-September-2019 6:18 PM ET,FCSTEV8-Aug-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Pharmacometrics Conference for 20-October-2019,FCSTEV8-Aug-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Oxford Global Advances In Immuno-Oncology USA Congress for 9-October-2019 3:00 PM ET,FCSTEV8-Aug-19,NKTR-US,Nektar Therapeutics Reports Financial Results for the Second Quarter of 2019,PRN4-Aug-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Cambridge Healthtech Institute Immuno Oncology Summit for 5-August-2019,FCSTEV1-Aug-19,NKTR-US,Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma,PRN31-Jul-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2019 Earnings Release for 8-August-2019 4:16 PM ET,FCSTEV31-Jul-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2019 Earnings Call for 8-August-2019 5:00 PM ET,FCSTEV30-Jul-19,NKTR-US,"Nektar to Announce Financial Results for the Second Quarter 2019 on Thursday, August 8, 2019, After Close of U.S.-Based Financial Markets",PRN24-Jul-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules International Drug Discovery Science & Technology Congress for 25-July-2019,FCSTEV13-Jun-19,NKTR-US,"First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology",PRN13-Jun-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules European Rheumatology Congress for 13-June-2019 8:00 AM ET,FCSTEV11-Jun-19,NKTR-US,Nektar Therapeutics to Host Webcast Conference Call with Immunology Expert for Analysts & Investors During 2019 European Congress of Rheumatology (EULAR 2019),PRN1-Jun-19,NKTR-US,Nektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at 2019 ASCO Annual Meeting,PRN24-May-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #2623 for 1-June-2019 9:00 AM ET,FCSTEV23-May-19,NKTR-US,"Nektar Announces the Launch of Inheris Biopharma, Inc.",PRN15-May-19,NKTR-US,Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting,PRN8-May-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules European Hematology Association Congress - Abstract # PS1208 for 15-June-2019 11:30 AM ET,FCSTEV8-May-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Poster 168b Abstract # TPS9601 for 3-June-2019 2:15 PM ET,FCSTEV8-May-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Poster 228 Abstract 2584 for 1-June-2019 9:00 AM ET,FCSTEV8-May-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules European Hematology Association Congress - Abstract # PS1208 for 15-June-2019 10:30 AM ET,FCSTEV8-May-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract # 11010 for 3-June-2019 12:30 PM ET,FCSTEV8-May-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Poster #416b Abstract # TPS4595 for 3-June-2019 2:15 PM ET,FCSTEV8-May-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Immuno Oncology Congress for 21-May-2019 11:30 AM ET,FCSTEV8-May-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Poster #267 Abstract # 2623 for 1-June-2019 9:00 AM ET,FCSTEV8-May-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Pharmaceutical & Bioscience Society Symposium for 11-June-2019 11:45 AM ET,FCSTEV8-May-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Drug Discovery Nexus Conference for 17-May-2019 9:30 AM ET,FCSTEV8-May-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules European Congress of Rheumatology Conference - Abstract # OP0195 for 13-June-2019 5:20 AM ET,FCSTEV8-May-19,NKTR-US,Nektar Therapeutics Reports Financial Results for the First Quarter of 2019,PRN3-May-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Annual General Meeting for 12-June-2019 5:00 PM ET,FCSTEV1-May-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2019 Earnings Call for 8-May-2019 5:00 PM ET,FCSTEV1-May-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2019 Earnings Release for 8-May-2019 4:10 PM ET,FCSTEV1-May-19,NKTR-US,"Nektar to Announce Financial Results for the First Quarter 2019 on Wednesday, May 8, 2019, After Close of U.S.-Based Financial Markets",PRN2-Apr-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules William Blair Late-Stage Therapeutics Conference for 4-April-2019,FCSTEV2-Apr-19,NKTR-US,Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019,PRN1-Apr-19,NKTR-US,Vaccibody AS and Nektar Therapeutics Present New Preclinical Data from their Immuno-Oncology Collaboration at the American Association for Cancer Research (AACR) Annual Meeting 2019,PRN27-Mar-19,NKTR-US,Biotechnology Companies Rush to Develop Treatments for Various Illnesses Found Globally,PRN7-Mar-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Cowen & Co. Health Care Conference for 12-March-2019 9:20 AM ET,FCSTEV6-Mar-19,NKTR-US,Nektar Therapeutics to Webcast Presentation at the Cowen and Company 39th Annual Health Care Conference,PRN4-Mar-19,NKTR-US,Biotechnology Companies see Rising Demand for new Therapies,CNW4-Mar-19,NKTR-US,"BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer",PMZ1-Mar-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules ASCO-SITC Clinical Immuno-Oncology Symposium - Abstract #28 for 1-March-2019 4:00 PM ET,FCSTEV1-Mar-19,NKTR-US,"Nektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting",PRN28-Feb-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Immunotherapy of Cancer Conference - Poster P2.12 for 12-April-2019 8:00 AM ET,FCSTEV28-Feb-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules ICI-IO Combinations Summit for 20-March-2019 11:30 AM ET,FCSTEV28-Feb-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules PEGS Boston Summit for 11-April-2019 1:50 PM ET,FCSTEV28-Feb-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Immunotherapy of Cancer Conference - Poster P2.12 for 11-April-2019 12:20 PM ET,FCSTEV28-Feb-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Keystone Immunotherapy Cancer Conference for 13-March-2019 11:00 AM ET,FCSTEV28-Feb-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules ASCO-SITC Clinical Immuno-Oncology Symposium for 1-March-2019 6:00 PM ET,FCSTEV28-Feb-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules CHI Immuno-Oncology Summit for 19-March-2019 12:45 PM ET,FCSTEV28-Feb-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules International Molecular Medicine Tri-Conference for 12-March-2019 2:25 PM ET,FCSTEV28-Feb-19,NKTR-US,Nektar Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results,PRN27-Feb-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract #3265 for 2-April-2019 8:00 AM ET,FCSTEV27-Feb-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract #2256 for 1-April-2019 1:00 PM ET,FCSTEV27-Feb-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract #3210 for 2-April-2019 8:00 AM ET,FCSTEV27-Feb-19,NKTR-US,Nektar Therapeutics Announces Several Preclinical Data Presentations for its Immuno-oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019,PRN25-Feb-19,NKTR-US,Nektar Therapeutics to Webcast Conference Call for Analysts and Investors at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium,PRN21-Feb-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2018 Earnings Call for 28-February-2019 5:00 PM ET,FCSTEV21-Feb-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2018 Earnings Release for 28-February-2019 4:10 PM ET,FCSTEV21-Feb-19,NKTR-US,"Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2018 on Thursday, February 28, 2019, After Close of U.S.-Based Financial Markets",PRN15-Feb-19,NKTR-US,Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium,PRN13-Feb-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Genitourinary Cancers Symposium for 15-February-2019 5:00 PM ET,FCSTEV13-Feb-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Genitourinary Cancers Symposium - Abstract #: 388 for 15-February-2019 8:15 PM ET,FCSTEV13-Feb-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Genitourinary Cancers Symposium - Abstract #: 388 for 15-February-2019 3:15 PM ET,FCSTEV11-Feb-19,NKTR-US,Nektar Therapeutics to Webcast Conference Call with Urothelial Cancer Specialist for Analysts & Investors at the 2019 ASCO Genitourinary Cancers Symposium,PRN30-Jan-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Immuno-Oncology 360° Conference for 6-February-2019,FCSTEV17-Jan-19,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Management Meeting - Jefferies for 18-January-2019,FCSTEV3-Jan-19,NKTR-US,ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics,PRN27-Dec-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Healthcare Conference for 8-January-2019 12:00 PM ET,FCSTEV27-Dec-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Healthcare Conference - Breakout Session for 8-January-2019 12:30 PM ET,FCSTEV27-Dec-18,NKTR-US,"Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN20-Dec-18,NKTR-US,NKTR DEADLINE ALERT: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important Deadline in Class Action - NKTR,PMZ20-Dec-18,NKTR-US,"CLASS ACTION UPDATE for DY, NKTR and TX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ14-Dec-18,NKTR-US,"SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR",PMZ13-Dec-18,NKTR-US,"CLASS ACTION UPDATE for IGCC, NKTR and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ12-Dec-18,NKTR-US,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Jianpu, Nektar, Honeywell, and Fitbit and Encourages Investors to Contact the Firm",PMZ12-Dec-18,NKTR-US,"Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit against Nektar Therapeutics, Inc.",BW11-Dec-18,NKTR-US,"Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Nektar Therapeutics, Inc.",BW11-Dec-18,NKTR-US,SHAREHOLDER ALERT: COST NKTR FIT RBBN SONS MGI ATUS CMCM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ10-Dec-18,NKTR-US,"Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Nektar Therapeutics, Inc. Investors",BW10-Dec-18,NKTR-US,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NKTR, GSKY, RBBN (SONS), MDR and TX",PMZ10-Dec-18,NKTR-US,"UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",PMZ10-Dec-18,NKTR-US,"LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm",PMZ9-Dec-18,NKTR-US,SHAREHOLDER ALERT: DY NKTR GSKY ATUS TX BA APHA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ7-Dec-18,NKTR-US,"SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR",PMZ7-Dec-18,NKTR-US,"CLASS ACTION UPDATE for IGCC, NKTR, FIT and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ7-Dec-18,NKTR-US,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, TRVN, GOOG, NKTR and RYAAY",PMZ6-Dec-18,NKTR-US,"Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Nektar Therapeutics, Inc. Investors (NKTR)",BW6-Dec-18,NKTR-US,SHAREHOLDER ALERT: JT TRVN HTHT OZK NKTR FIT GSKY ATUS PPDF MAR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ5-Dec-18,NKTR-US,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HTHT, DY, ALGN, NKTR and SYF",PMZ4-Dec-18,NKTR-US,NKTR ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics; Important Deadline - NKTR,PRN3-Dec-18,NKTR-US,SHAREHOLDER ALERT: JT TRVN GOOG CWH OZK NKTR SYF AQUA GSKY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ3-Dec-18,NKTR-US,"INVESTOR NOTICE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",PMZ2-Dec-18,NKTR-US,"CLASS ACTION UPDATE for GOOG, OZK, IGCC and NKTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ30-Nov-18,NKTR-US,"SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR",PMZ30-Nov-18,NKTR-US,"LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm",PMZ30-Nov-18,NKTR-US,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GOOG, OZK, NKTR, FIT and TSRO",PMZ28-Nov-18,NKTR-US,"Glancy Prongay & Murray LLP Announces Investigation on Behalf of Nektar Therapeutics, Inc. Investors",BW28-Nov-18,NKTR-US,"CLASS ACTION UPDATE for NKTR, GSKY and RBBN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ27-Nov-18,NKTR-US,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Nektar Therapeutics, Inc. Investors (NKTR)",BW26-Nov-18,NKTR-US,SHAREHOLDER ALERT: HAS CPB ADNT SFIX GOOG CWH OZK NKTR AQUA RBBN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ23-Nov-18,NKTR-US,"SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR",PMZ20-Nov-18,NKTR-US,"CLASS ACTION UPDATE for JT, NKTR and AQUA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ20-Nov-18,NKTR-US,NKTR NOTICE ALERT: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important Deadline in Class Action Seeking Investor Losses - NKTR,BW19-Nov-18,NKTR-US,"Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors",PMZ18-Nov-18,NKTR-US,SHAREHOLDER ALERT: TGTX ABBV MGTI HAS CPB CHGG ADNT GOOG NKTR SYF RBBN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ16-Nov-18,NKTR-US,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR",PMZ14-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Jefferies Health Care Conference for 14-November-2018 5:00 AM ET,FCSTEV14-Nov-18,NKTR-US,"Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs",PRN14-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Hematology Meeting - Publication #2952 for 2-December-2018 9:00 PM ET,FCSTEV12-Nov-18,NKTR-US,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bank OZK, Nektar, and Honeywell and Encourages Investors to Contact the Firm",PMZ12-Nov-18,NKTR-US,SHAREHOLDER ALERT: APOG COCP ABBV COST HTHT SFIX CWH OZK NKTR SYF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ11-Nov-18,NKTR-US,"CLASS ACTION UPDATE for APOG, NKTR and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ10-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P424 for 10-November-2018 8:00 AM ET,FCSTEV10-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P348 for 10-November-2018 8:00 AM ET,FCSTEV10-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P368 for 10-November-2018 8:00 AM ET,FCSTEV10-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P364 for 10-November-2018 8:00 AM ET,FCSTEV10-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P418 for 10-November-2018 8:00 AM ET,FCSTEV10-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P557 for 10-November-2018 8:00 AM ET,FCSTEV10-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P419 for 10-November-2018 8:00 AM ET,FCSTEV9-Nov-18,NKTR-US,"SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR",PMZ9-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P364 for 10-November-2018,FCSTEV9-Nov-18,NKTR-US,Robbins Arroyo LLP: Nektar Therapeutics (NKTR) Misled Shareholders According to Class Action,BW9-Nov-18,NKTR-US,Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting,PRN9-Nov-18,NKTR-US,"Kessler Topaz Meltzer & Check, LLP:  Securities Fraud Class Action Filed Against Nektar Therapeutics - NKTR",PRN9-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P418 for 9-November-2018 8:00 AM ET,FCSTEV9-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P364 for 9-November-2018 8:00 AM ET,FCSTEV9-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P422 for 9-November-2018 8:00 AM ET,FCSTEV9-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P424 for 9-November-2018 8:00 AM ET,FCSTEV9-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P419 for 9-November-2018 8:00 AM ET,FCSTEV9-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P368 for 9-November-2018 8:00 AM ET,FCSTEV9-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P557 for 9-November-2018 8:00 AM ET,FCSTEV9-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P378 for 9-November-2018 8:00 AM ET,FCSTEV9-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P348 for 9-November-2018 8:00 AM ET,FCSTEV8-Nov-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P419 for 9-November-2018,FCSTEV8-Nov-18,NKTR-US,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COCP, SFIX, CWH, HON, NKTR and SYF",PMZ8-Nov-18,NKTR-US,"Kessler Topaz Meltzer & Check, LLP - Reminds Investors of Securities Fraud Class Action Lawsuit Against Nektar Therapeutics",BW7-Nov-18,NKTR-US,Nektar Therapeutics Reports Financial Results for the Third Quarter of 2018,PRN6-Nov-18,NKTR-US,"Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against Nektar Therapeutics",PMZ6-Nov-18,NKTR-US,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TRVN, HON, OZK and NKTR",PMZ6-Nov-18,NKTR-US,NKTR LOSS ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics; Important Deadline - NKTR,PMZ6-Nov-18,NKTR-US,"New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers",PRN6-Nov-18,NKTR-US,Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialists for Analysts & Investors During 2018 Society for Immunotherapy of Cancer 33rd Annual Meeting,PRN5-Nov-18,NKTR-US,"INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",PMZ5-Nov-18,NKTR-US,SHAREHOLDER ALERT: PVG USAT COCP JT GOOG OZK NKTR FIT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines,PMZ4-Nov-18,NKTR-US,"CLASS ACTION UPDATE for HON, DY, NKTR and FIT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ4-Nov-18,NKTR-US,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR",PMZ31-Oct-18,NKTR-US,Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR),PMZ31-Oct-18,NKTR-US,"CLASS ACTION UPDATE for TGTX, HAS and NKTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",PMZ31-Oct-18,NKTR-US,SOFTHALE NV annonce un nouveau membre de son conseil d'administration,PRNE31-Oct-18,NKTR-US,SOFTHALE NV gibt neues Vorstandsmitglied bekannt,PRNE30-Oct-18,NKTR-US,EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR,BW30-Oct-18,NKTR-US,"Pomerantz Law Firm Announces the Filing of a Class Action against Nektar Therapeutics, Inc. and Certain Officers - NKTR",PMZ30-Oct-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2018 Earnings Call for 7-November-2018 5:00 PM ET,FCSTEV30-Oct-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2018 Earnings Release for 7-November-2018 4:10 PM ET,FCSTEV30-Oct-18,NKTR-US,"Nektar to Announce Financial Results for the Third Quarter 2018 on Wednesday, November 7, 2018, After Close of U.S.-Based Financial Markets",PRN23-Oct-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules TraceLink Futurelink Conference for 6-November-2018,FCSTEV12-Oct-18,NKTR-US,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR,PMZ5-Oct-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P348 for 10-November-2018 9:00 AM ET,FCSTEV5-Oct-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P424 for 10-November-2018 8:00 AM ET,FCSTEV5-Oct-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P378 for 10-November-2018 8:00 AM ET,FCSTEV5-Oct-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P422 for 10-November-2018 8:00 AM ET,FCSTEV5-Oct-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P368 for 10-November-2018 8:00 AM ET,FCSTEV5-Oct-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P419 for 10-November-2018 8:00 AM ET,FCSTEV5-Oct-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P364 for 10-November-2018 8:00 AM ET,FCSTEV5-Oct-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P418 for 10-November-2018 8:00 AM ET,FCSTEV5-Oct-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract: #O4 for 9-November-2018 5:05 PM ET,FCSTEV5-Oct-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P348 for 10-November-2018 8:00 AM ET,FCSTEV5-Oct-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract P557 for 10-November-2018 8:00 AM ET,FCSTEV5-Oct-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Pharmacometrics Conference for 6-October-2018,FCSTEV3-Oct-18,NKTR-US,Nektar Therapeutics (NKTR) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws,PRN2-Oct-18,NKTR-US,Nektar Therapeutics Announces Ten Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting,PRN1-Oct-18,NKTR-US,Nektar Therapeutics Strengthens Board of Directors with Appointment of Veteran Biotechnology Executive Karin Eastham,PRN26-Sep-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules SMI Immuno Oncology Conference for 26-September-2018 6:00 AM ET,FCSTEV24-Sep-18,NKTR-US,BioXcel Therapeutics Expands Immuno-Oncology Partnership with Nektar into Clinical Development in Pancreatic Cancer,PMZ31-Aug-18,NKTR-US,"Market Trends Toward New Normal in Caesars Entertainment, Nektar Therapeutics, Boston Scientific, Apollo Commercial Real Estate Finance, Kellogg, and Foot Locker - Emerging Consolidated Expectations, Analyst Ratings",PMZ16-Aug-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Morgan Stanley Global Health Care Conference for 12-September-2018 8:45 AM ET,FCSTEV8-Aug-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules European Society for Medical Oncology Meeting - Poster #446TiP for 22-October-2018 6:45 AM ET,FCSTEV8-Aug-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Chemical Society Meeting for 20-August-2018 1:35 PM ET,FCSTEV8-Aug-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules European Society for Medical Oncology Meeting - Poster #362TiP for 22-October-2018 6:45 AM ET,FCSTEV8-Aug-18,NKTR-US,Nektar Therapeutics Reports Financial Results for the Second Quarter of 2018,PRN1-Aug-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2018 Earnings Release for 8-August-2018 4:10 PM ET,FCSTEV1-Aug-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2018 Earnings Call for 8-August-2018 5:00 PM ET,FCSTEV1-Aug-18,NKTR-US,"Nektar to Announce Financial Results for the Second Quarter 2018 on Wednesday, August 8, 2018, After Close of U.S.-Based Financial Markets",PRN31-Jul-18,NKTR-US,Specialty Oncology Drugs One of the Top Markets Generating Most Growth,PRN30-Jul-18,NKTR-US,Nektar Therapeutics Announces New Drug Application for NKTR-181 Accepted for Review by FDA,PRN26-Jul-18,NKTR-US,"Investor Expectations to Drive Momentum within Fidelity Southern, Nektar Therapeutics, CSG Systems International, Ellington Financial, NBT, and Paylocity Holding - Discovering Underlying Factors of Influence",PMZ26-Jun-18,NKTR-US,IsoPlexis Announces Research Collaboration with Nektar Therapeutics,PRN14-Jun-18,NKTR-US,"New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th Annual Scientific Meeting",PRN13-Jun-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules William Blair Growth Stock Conference for 13-June-2018 9:40 AM ET,FCSTEV5-Jun-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Jefferies Global Healthcare Conference for 6-June-2018 3:00 PM ET,FCSTEV5-Jun-18,NKTR-US,Nektar to Webcast Presentation at the Jefferies 2018 Healthcare Conference in New York,PRN4-Jun-18,NKTR-US,"BioXcel Therapeutics and Nektar Therapeutics Present Preclinical Pancreatic Cancer Data for BXCL701, NKTR-214 and Anti-PD1 Combination Therapy at ASCO 2018 Annual Meeting",PMZ2-Jun-18,NKTR-US,"Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018",PRN31-May-18,NKTR-US,"Nektar Therapeutics Announces Submission of a New Drug Application to the U.S. FDA for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy",PRN30-May-18,NKTR-US,Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration,PRN18-May-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract: #3006 for 2-June-2018 6:00 PM ET,FCSTEV18-May-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #2567 for 4-June-2018 9:00 AM ET,FCSTEV18-May-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract # 3006 for 2-June-2018 6:00 PM ET,FCSTEV17-May-18,NKTR-US,BioXcel Therapeutics Announces Data Presentation at ASCO 2018 Annual Meeting,PMZ16-May-18,NKTR-US,Nektar Therapeutics Announces Six Abstracts Accepted for Presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting,PRN10-May-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #TPS3115 for 4-June-2018 9:00 AM ET,FCSTEV10-May-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #TPS1111 for 2-June-2018 9:00 AM ET,FCSTEV10-May-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #2567 for 4-June-2018 9:00 AM ET,FCSTEV10-May-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #5582 for 4-June-2018 2:15 PM ET,FCSTEV10-May-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #3006 for 2-June-2018 4:00 PM ET,FCSTEV10-May-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #3085 for 4-June-2018 9:00 AM ET,FCSTEV10-May-18,NKTR-US,Nektar Therapeutics Reports Financial Results for the First Quarter of 2018,PRN8-May-18,NKTR-US,"Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus",PRN3-May-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2018 Earnings Call for 10-May-2018 5:00 PM ET,FCSTEV3-May-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2018 Earnings Release for 10-May-2018 4:10 PM ET,FCSTEV3-May-18,NKTR-US,"Nektar to Announce Financial Results for the First Quarter 2018 on Thursday, May 10, 2018, After Close of U.S.-Based Financial Markets",PRN2-May-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Annual General Meeting for 26-June-2018 2:00 PM ET,FCSTEV1-May-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - NKTR-214 for 2-June-2018 6:00 PM ET,FCSTEV30-Apr-18,NKTR-US,Nektar Therapeutics to Host Analyst & Investor Event at 2018 ASCO Annual Meeting,PRN24-Apr-18,NKTR-US,"New Oncology Clinical Collaboration between Nektar and Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist, and TAK-659, a Dual SYK and FLT-3 Inhibitor, in Liquid and Solid Tumors",PRN18-Apr-18,NKTR-US,"Free Research Reports on These Biotech Stocks -- Moleculin Biotech, MyoKardia, Nektar Therapeutics, and Novavax",PRN15-Apr-18,NKTR-US,Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2018,PRN11-Apr-18,NKTR-US,Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors,PRN10-Apr-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Health Care Conference for 8-May-2018 8:40 AM ET,FCSTEV3-Apr-18,NKTR-US,Nektar Therapeutics Announces Effective Date of Global Development & Commercialization Collaboration with Bristol-Myers Squibb,PRN3-Apr-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules William Blair & Company Cancer Immunotherapy Conference - Panel for 4-April-2018 11:35 AM ET,FCSTEV9-Mar-18,NKTR-US,"Take-Two Interactive Software, SVB Financial and Nektar Pharmaceuticals Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600",PRN7-Mar-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Cowen & Co. Health Care Conference for 14-March-2018 8:00 AM ET,FCSTEV7-Mar-18,NKTR-US,Nektar to Webcast Presentation at the Cowen and Company 38th Annual Health Care Conference in Boston,PRN6-Mar-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Advances in Immuno-Oncology Congress for 24-May-2018 12:40 PM ET,FCSTEV6-Mar-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Academy of Pain Medicine Meeting for 27-April-2018 9:00 PM ET,FCSTEV2-Mar-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract - 3755 for 17-April-2018 9:00 AM ET,FCSTEV2-Mar-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract - 2755 for 16-April-2018 2:00 PM ET,FCSTEV2-Mar-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract - 123 for 15-April-2018 2:00 PM ET,FCSTEV2-Mar-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract - 3566 for 17-April-2018 9:00 AM ET,FCSTEV1-Mar-18,NKTR-US,Nektar Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results,PRN1-Mar-18,NKTR-US,Nektar Therapeutics to Host Earnings Call,NEWS_ACW21-Feb-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2017 Earnings Call for 1-March-2018 5:00 PM ET,FCSTEV21-Feb-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2017 Earnings Release for 1-March-2018 4:10 PM ET,FCSTEV21-Feb-18,NKTR-US,"Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2017 on Thursday, March 1, 2018, After Close of U.S.-Based Financial Markets",PRN15-Feb-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting for 14-April-2018,FCSTEV15-Feb-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #3755 for 2-June-2018 7:45 PM ET,FCSTEV14-Feb-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules NKTR-214 Plus Opdivo Update Call for 14-February-2018 8:00 AM ET,FCSTEV14-Feb-18,NKTR-US,"Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar's CD122-biased Agonist, NKTR-214",BW3-Jan-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Health Care Conference for 9-January-2018 2:00 PM ET,FCSTEV3-Jan-18,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Health Care Conference - Q&A Session for 9-January-2018 2:30 PM ET,FCSTEV3-Jan-18,NKTR-US,"Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN20-Dec-17,NKTR-US,Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance,BW27-Nov-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Piper Jaffray Health Care Conference for 28-November-2017 5:10 PM ET,FCSTEV27-Nov-17,NKTR-US,Nektar to Webcast Presentation at the Piper Jaffray 29th Annual Healthcare Conference in New York City,PRN22-Nov-17,NKTR-US,Nektar Announces Key Executive Promotions to Drive the Continued Growth of the Company's Immuno-Oncology Pipeline,PRN12-Nov-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting for 12-November-2017 6:15 AM ET,FCSTEV11-Nov-17,NKTR-US,"First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017",PRN11-Nov-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting for 11-November-2017 5:00 PM ET,FCSTEV11-Nov-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P140 for 11-November-2017 12:30 PM ET,FCSTEV11-Nov-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P434 for 11-November-2017 12:30 PM ET,FCSTEV11-Nov-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P332 for 11-November-2017 12:30 PM ET,FCSTEV11-Nov-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P274 for 11-November-2017 12:30 PM ET,FCSTEV10-Nov-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P275 for 10-November-2017 12:30 PM ET,FCSTEV10-Nov-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P77 for 10-November-2017 12:30 PM ET,FCSTEV10-Nov-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Jefferies London Health Care Conference for 15-November-2017 5:00 AM ET,FCSTEV10-Nov-17,NKTR-US,Nektar to Webcast Presentation at Jefferies 2017 London Healthcare Conference,PRN7-Nov-17,NKTR-US,Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017,PRN7-Nov-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American College of Rheumatology Meeting - Abstract 2715 for 7-November-2017 12:00 PM ET,FCSTEV7-Nov-17,NKTR-US,New Data Featuring Nektar Therapeutics' Wholly-Owned Immuno-Oncology Pipeline to be Presented at the 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting,PRN7-Nov-17,NKTR-US,"Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 2017 American College of Rheumatology Annual Meeting",PRN1-Nov-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting for 11-November-2017 6:15 PM ET,FCSTEV1-Nov-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #P434 for 1-November-2017 12:30 PM ET,FCSTEV31-Oct-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2017 Earnings Call for 7-November-2017 5:00 PM ET,FCSTEV31-Oct-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2017 Earnings Release for 7-November-2017 4:10 PM ET,FCSTEV31-Oct-17,NKTR-US,"Nektar to Announce Financial Results for the Third Quarter of 2017 on Tuesday, November 7, 2017, After Close of U.S.-Based Financial Markets",PRN21-Sep-17,NKTR-US,Nektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member,PRN21-Sep-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Society for Immunotherapy of Cancer Meeting - Abstract #PIVOT-02 for 11-November-2017 3:30 PM ET,FCSTEV20-Sep-17,NKTR-US,Nektar Therapeutics Announces Seven Abstracts Accepted for Presentation at 2017 Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting,PRN12-Sep-17,NKTR-US,"Nektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with TECENTRIQ® (atezolizumab) or KEYTRUDA® (pembrolizumab)",PRN9-Sep-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules European Society for Medical Oncology Congress for 9-September-2017 7:15 AM ET,FCSTEV6-Sep-17,NKTR-US,"Nektar Therapeutics Presents Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2017 PAINWeek®",PRN6-Sep-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Morgan Stanley Global Healthcare Conference for 12-September-2017 12:55 PM ET,FCSTEV6-Sep-17,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2017 Morgan Stanley Global Healthcare Conference in New York City",PRN30-Aug-17,NKTR-US,"Nektar Therapeutics to Present Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at PAINWeek®",PRN8-Aug-17,NKTR-US,Nektar Therapeutics Reports Financial Results for the Second Quarter of 2017,PRN8-Aug-17,NKTR-US,Investor Network: Nektar Therapeutics to Host Earnings Call,NEWS_ACW2-Aug-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2017 Earnings Call for 8-August-2017 5:00 PM ET,FCSTEV2-Aug-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2017 Earnings Release for 8-August-2017 4:10 PM ET,FCSTEV2-Aug-17,NKTR-US,"Nektar to Announce Financial Results for the Second Quarter of 2017 on Tuesday, August 8, 2017, After Close of U.S.-Based Financial Markets",PRN24-Jul-17,NKTR-US,"Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy",PRN18-Jul-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules NKTR-181 Human Abuse Potential Study Results Call for 18-July-2017 8:45 AM ET,FCSTEV18-Jul-17,NKTR-US,"Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain",PRN10-Jul-17,NKTR-US,"Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London",PRN13-Jun-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Annual General Meeting for 14-June-2017,FCSTEV6-Jun-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Jefferies Global Health Care Conference for 7-June-2017 9:30 AM ET,FCSTEV6-Jun-17,NKTR-US,Nektar to Webcast Presentation at Jefferies 2017 Global Healthcare Conference in New York City,PRN5-Jun-17,NKTR-US,"Nektar Presents New Clinical Data from Two Studies of NKTR-214, a CD122-Biased Agonist, at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting",PRN22-May-17,NKTR-US,"New Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy Approaches with NKTR-214, a CD122-Biased Agonist, and Five Takeda Cancer Therapy Compounds",PRN18-May-17,NKTR-US,Nektar Therapeutics Announces Data Presentations at ASCO 2017,PRN15-May-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules UBS Global Health Care Conference for 22-May-2017 1:30 PM ET,FCSTEV15-May-17,NKTR-US,Nektar to Webcast Presentation at UBS Global Healthcare Conference 2017 in New York,PRN9-May-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract TPS1120 for 4-June-2017 9:00 AM ET,FCSTEV9-May-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract 2545 for 5-June-2017 9:00 AM ET,FCSTEV9-May-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract# e14040 for 4-June-2017,FCSTEV9-May-17,NKTR-US,Nektar Therapeutics Reports Financial Results for the First Quarter of 2017,PRN9-May-17,NKTR-US,Investor Network: Nektar Therapeutics to Host Earnings Call,NEWS_ACW3-May-17,NKTR-US,"Nektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program",PRN2-May-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2017 Earnings Release for 9-May-2017 4:10 PM ET,FCSTEV2-May-17,NKTR-US,"Nektar to Announce Financial Results for the First Quarter of 2017 on Tuesday, May 9, 2017, After Close of U.S.-Based Financial Markets",PRN20-Apr-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract e14040 for 3-June-2017 7:00 PM ET,FCSTEV20-Apr-17,NKTR-US,Nektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting,PRN10-Apr-17,NKTR-US,Today's Research Reports on Biotech Stocks to Watch: Nektar Therapeutics and Clovis Oncology,NEWS_ACW4-Apr-17,NKTR-US,Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting,PRN27-Mar-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract 1603 for 3-April-2017 8:00 AM ET,FCSTEV27-Mar-17,NKTR-US,"Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders",PRN21-Mar-17,NKTR-US,Stocks of Nektar Therapeutics and CytomX Therapeutics Rise on FDA Trial News,NEWS_ACW20-Mar-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules NKTR-181 Phase 3 Study Results Call for 20-March-2017 8:45 AM ET,FCSTEV20-Mar-17,NKTR-US,NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain,PRN14-Mar-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract 2671 for 3-April-2017 1:00 PM ET,FCSTEV14-Mar-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract 1603 for 3-April-2017 8:00 AM ET,FCSTEV14-Mar-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract 1604 for 3-April-2017 8:00 AM ET,FCSTEV14-Mar-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract 1617 for 3-April-2017 8:00 AM ET,FCSTEV14-Mar-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract 1598 for 3-April-2017 8:00 AM ET,FCSTEV7-Mar-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Cowen and Company Global Health Care Conference for 7-March-2017 11:20 AM ET,FCSTEV2-Mar-17,NKTR-US,Nektar to Webcast Presentation at Cowen and Company's 37th Annual Health Care Conference in Boston,PRN1-Mar-17,NKTR-US,Nektar Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting,PRN1-Mar-17,NKTR-US,Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results,PRN22-Feb-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2016 Earnings Call for 1-March-2017 5:00 PM ET,FCSTEV22-Feb-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2016 Earnings Release for 1-March-2017 4:10 PM ET,FCSTEV22-Feb-17,NKTR-US,"Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2016 on Wednesday, March 1, 2017, After Close of U.S.-Based Financial Markets",PRN18-Feb-17,NKTR-US,Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium,PRN25-Jan-17,NKTR-US,Biotech Industry a Focus in 2017: Latest Reports on Nektar Therapeutics and Acasti Pharma,NEWS_ACW5-Jan-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Health Care Conference for 10-January-2017 5:00 PM ET,FCSTEV5-Jan-17,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Health Care Conference - Q&A Session for 10-January-2017 5:30 PM ET,FCSTEV5-Jan-17,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN11-Dec-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules BMO Capital Markets Prescriptions for Success Healthcare Conference. for 14-December-2016,FCSTEV18-Nov-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules RBC Capital Markets' Healthcare Investor Day for 15-December-2016,FCSTEV14-Nov-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Jefferies London Health Care Conference for 16-November-2016 8:20 AM ET,FCSTEV14-Nov-16,NKTR-US,Nektar Therapeutics to Present at Jefferies 2016 Global Healthcare Conference in London,PRN9-Nov-16,NKTR-US,Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting,PRN4-Nov-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules ROTH Capital Partners Innovations in Oncology Corporate Access Day for 17-November-2016,FCSTEV3-Nov-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Sy for 30-November-2016 2:30 AM ET,FCSTEV3-Nov-16,NKTR-US,Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016,PRN28-Oct-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Investor and Analyst Meeting for 9-November-2016 2:30 PM ET,FCSTEV28-Oct-16,NKTR-US,Nektar to Hold Investor & Analyst Event at 2016 Society for Immunotherapy of Cancer Annual Meeting,PRN28-Oct-16,NKTR-US,Nektar Therapeutics Announces Upcoming Presentations at the 2016 Society for Immunotherapy of Cancer Annual Meeting,PRN27-Oct-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2016 Earnings Call for 3-November-2016 5:00 PM ET,FCSTEV27-Oct-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2016 Earnings Release for 3-November-2016 4:10 PM ET,FCSTEV27-Oct-16,NKTR-US,"Nektar to Announce Financial Results for the Third Quarter 2016 on Thursday, November 3, 2016, After Close of U.S.-Based Financial Markets",PRN18-Oct-16,NKTR-US,Nektar Therapeutics Prices Public Offering of Shares of Common Stock,PRN18-Oct-16,NKTR-US,Technologie von Aerogen reduziert Klinikeinlieferungen aus der Notaufnahme um 32 Prozent1,BW18-Oct-16,NKTR-US,La technologie Aerogen réduit de 32 % les admissions en services d'urgence1,BW17-Oct-16,NKTR-US,Nektar Therapeutics Announces Public Offering of Shares of Common Stock,PRN27-Sep-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Nektar Therapeutics and Bristol-Myers Squibb New Clinical Collaboration Call for 27-September-2016 9:00 AM ET,FCSTEV27-Sep-16,NKTR-US,Nektar Therapeutics to Host Investor & Analyst Conference Call to Discuss New Clinical Collaboration with Bristol-Myers Squibb,PRN27-Sep-16,NKTR-US,Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214,BW3-Aug-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules European Society for Medical Oncology Congress - Abstract #3048 for 9-October-2016 2:00 PM ET,FCSTEV3-Aug-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference - Abstract#311 for 26-September-2016 5:15 PM ET,FCSTEV3-Aug-16,NKTR-US,Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016,PRN3-Aug-16,NKTR-US,"Biotech Stocks Technical Report -- Arena Pharma, BIND Therapeutics, Nektar Therapeutics, and Regeneron Pharma",PRN27-Jul-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2016 Earnings Call for 3-August-2016 5:00 PM ET,FCSTEV27-Jul-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2016 Earnings Release for 3-August-2016 4:15 PM ET,FCSTEV27-Jul-16,NKTR-US,"Nektar to Announce Financial Results for the Second Quarter 2016 on Wednesday, August 3, 2016, After Close of U.S.-Based Financial Markets",PRN6-Jun-16,NKTR-US,Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity,PRN6-Jun-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Roth Health Care Day for 22-June-2016,FCSTEV3-Jun-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Jefferies Health Care Conference for 8-June-2016 11:30 AM ET,FCSTEV2-Jun-16,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2016 Global Healthcare Conference in New York City",PRN2-Jun-16,NKTR-US,Nektar Therapeutics Announces Executive Management Promotions,PRN1-Jun-16,NKTR-US,"Nektar Therapeutics and Daiichi Sankyo Europe GmbH Sign European Licensing Agreement for ONZEALD™ (etirinotecan pegol), an Investigational Drug Candidate Being Developed to Treat Patients with Advanced Breast Cancer and Brain Metastases",PRN19-May-16,NKTR-US,"DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit Against NantKwest, Inc. And Reminds Investors With Losses To Contact The Firm",NEWS_ACW19-May-16,NKTR-US,"DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nantkwest, Inc. (NK) and Lead Plaintiff Deadline: May 23, 2016",NEWS_ACW17-May-16,NKTR-US,"IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against NantKwest, Inc. And Encourages Investors With Losses To Contact The Firm",NEWS_ACW11-May-16,NKTR-US,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Nantkwest, Inc. (NK) and Lead Plaintiff Deadline: May 23, 2016",NEWS_ACW3-May-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting for 24-May-2016,FCSTEV3-May-16,NKTR-US,Nektar Therapeutics Reports Financial Results for the First Quarter of 2016,PRN3-May-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Annual General Meeting for 23-June-2016,FCSTEV29-Apr-16,NKTR-US,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NantKwest, Inc. of Class Action Lawsuit and Upcoming Deadline - NK",NEWS_ACW28-Apr-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2016 Earnings Call for 3-May-2016 4:30 PM ET,FCSTEV28-Apr-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2016 Earnings Release for 3-May-2016 After Market Hours ET,FCSTEV28-Apr-16,NKTR-US,"Nektar to Announce Financial Results for the First Quarter 2016 on Tuesday, May 3, 2016, After Close of U.S.-Based Financial Markets",PRN25-Apr-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Health Care Conference for 5-May-2016 8:40 AM ET,FCSTEV22-Apr-16,NKTR-US,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NantKwest, Inc. of Class Action Lawsuit and Upcoming Deadline - NK",NEWS_ACW18-Apr-16,NKTR-US,Preclinical Data Presented at AACR Demonstrate that Combining NKTR-214 with Checkpoint Blockade is Superior to Dual Checkpoint Inhibition in Increasing Clonality of the T Cell Receptor (TCR) Repertoire and T Cell Tumor Infiltration,PRN6-Apr-16,NKTR-US,"INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of NantKwest, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 23, 2016 - NK",NEWS_ACW1-Apr-16,NKTR-US,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NantKwest, Inc. of Class Action Lawsuit and Upcoming Deadline - NK",NEWS_ACW3-Mar-16,NKTR-US,"Nektar Therapeutics to Present at Cowen and Company's 36th Annual Health Care Conference in Boston, MA",PRN2-Mar-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract 558 for 17-April-2016 2:00 PM ET,FCSTEV1-Mar-16,NKTR-US,Nektar Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results,PRN26-Feb-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2015 Earnings Call for 1-March-2016 5:00 PM ET,FCSTEV26-Feb-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2015 Earnings Release for 1-March-2016 After Market Hours ET,FCSTEV26-Feb-16,NKTR-US,"Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2015 on Tuesday, March 1, 2016, After Close of U.S.-Based Financial Markets",PRN25-Feb-16,NKTR-US,Baxalta Announces Submission of Supplemental BLAs to Expand Use of ADYNOVATE to Pediatric Patients and Surgical Settings,PRN19-Feb-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Cowen and Company Health Care Conference for 9-March-2016 8:40 AM ET,FCSTEV1-Feb-16,NKTR-US,"Nektar Publishes Pre-clinical Results for NKTR-214, an Investigational CD122-Biased Immune-Stimulatory Cytokine for the Treatment of Cancer in Clinical Cancer Research",PRN25-Jan-16,NKTR-US,"Technical Recap on Biotechnology Stocks -- Nektar Therapeutics, Novavax, Celgene, and Opko Health",NEWS_ACW7-Jan-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Health Care Conference - Q&A Session for 12-January-2016 2:30 PM ET,FCSTEV6-Jan-16,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Health Care Conference for 12-January-2016 2:00 PM ET,FCSTEV6-Jan-16,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN24-Dec-15,NKTR-US,"Factors Moving Markets - Featured Research on NantKwest, KEYW Holding, NOODLES & CO, and CAI International",NEWS_ACW21-Dec-15,NKTR-US,Baxalta's ADYNOVATE Meets Endpoints in Phase 3 Study of Hemophilia A Patients Under 12 Years of Age,PRN10-Dec-15,NKTR-US,"A Change in Tides - Complementary Research on Nektar, California Resources, Zynga and Finisar",NEWS_ACW9-Dec-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules ROTH Capital Partners Immuno-Oncology Corporate Access Day for 16-December-2015,FCSTTS8-Dec-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Oppenheimer Health Care Conference for 9-December-2015 1:00 PM ET,FCSTTS8-Dec-15,NKTR-US,Nektar Therapeutics to Present at Oppenheimer 26th Annual Healthcare Conference in New York,PRN8-Dec-15,NKTR-US,"Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine",PRN30-Nov-15,NKTR-US,"Baxalta Announces U.S. Availability of ADYNOVATE, A New Treatment for Adult Patients with Hemophilia A With a Simple, Twice-Weekly Dosing Schedule",PRN17-Nov-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Jefferies Autumn Global Health Care Conference for 19-November-2015 11:40 AM ET,FCSTTS17-Nov-15,NKTR-US,Nektar Therapeutics to Present at Jefferies Autumn 2015 Global Healthcare Conference in London,PRN5-Nov-15,NKTR-US,Nektar Therapeutics Reports Financial Results for the Third Quarter of 2015,PRN29-Oct-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2015 Earnings Release for 5-November-2015 After Market Hours ET,FCSTTS29-Oct-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2015 Earnings Call for 5-November-2015 5:00 PM ET,FCSTTS29-Oct-15,NKTR-US,"Nektar to Announce Financial Results for the Third Quarter 2015 on Thursday, November 5, 2015, After Close of U.S.-Based Financial Markets",PRN8-Oct-15,NKTR-US,Nektar Reports on Advancements with Pain and Oncology Clinical Pipeline at Investor and Analyst R&D Day,PRN7-Oct-15,NKTR-US,Nektar Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies,PRN6-Oct-15,NKTR-US,Nektar Closes Direct Private Placement with TPG Special Situations Partners of $250 Million of Senior Secured Notes Due in 2020,PRN1-Oct-15,NKTR-US,Nektar to Host Research & Development Day for Analysts and Investors on October 8th,PRN21-Sep-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Ladenburg Thalmann Health Care Conference for 29-September-2015 3:00 PM ET,FCSTTS21-Sep-15,NKTR-US,"Nektar Presents Data Demonstrating that NKTR-214, a CD122-Biased Immunostimulatory Cytokine, Induces Durable and Specific Anti-Tumor Immunity As a Single-Agent and When Combined with Checkpoint Inhibitors in Preclinical Models",PRN1-Sep-15,NKTR-US,Nektar Announces Receipt of $40 Million Milestone Payment Resulting from First Commercial Sale of MOVENTIG® (naloxegol) Tablets in Major European Market,PRN10-Aug-15,NKTR-US,"New Webinar on Leveraging Private Social Networking Technology to Maintain Clinical Trial Oversight, Hosted by Xtalks",INW7-Aug-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules AACR Inaugural International Cancer Immunotherapy Conference for 18-September-2015 4:30 PM ET,FCSTTS5-Aug-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules R&D Day for 8-October-2015 12:30 PM ET,FCSTEV5-Aug-15,NKTR-US,Nektar Therapeutics Reports Financial Results for the Second Quarter of 2015,PRN31-Jul-15,NKTR-US,"Biotechnology Stocks on our Scanner -- Agenus, RXi Pharma, Nektar Therapeutics, Genetic Technologies, and Agios Pharma",PRN29-Jul-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2015 Earnings Call for 5-August-2015 5:00 PM ET,FCSTTS29-Jul-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2015 Earnings Release for 5-August-2015 After Market Hours ET,FCSTTS29-Jul-15,NKTR-US,"Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets",PRN16-Jul-15,NKTR-US,Baxalta's BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A,PRN2-Jun-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Jefferies Global Healthcare Conference - Q & A Session for 2-June-2015 9:00 AM ET,FCSTTS2-Jun-15,NKTR-US,"Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine",PRN28-May-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Jefferies Global Healthcare Conference for 2-June-2015 8:30 AM ET,FCSTTS28-May-15,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2015 Global Healthcare Conference in New York City",PRN7-May-15,NKTR-US,"Financial Results Galore: Complementary Research on Accuracy Inc., Teradyne, Nektar, Century Aluminum and Newpark Resources",PRN4-May-15,NKTR-US,"Critical Alerts For American Airlines, Nektar Therapeutics, Ocwen Financial, Skyworks Solutions and Chevron Released By InvestorsObserver",PRN2-May-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Annual General Meeting for 16-June-2015,FCSTTS30-Apr-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract # 1001 for 1-June-2015 4:12 PM ET,FCSTTS30-Apr-15,NKTR-US,Nektar Therapeutics Reports Financial Results for the First Quarter of 2015,PRN23-Apr-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2015 Earnings Release for 30-April-2015 After Market Hours ET,FCSTTS23-Apr-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2015 Earnings Call for 30-April-2015 5:00 PM ET,FCSTTS23-Apr-15,NKTR-US,"Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets",PRN16-Apr-15,NKTR-US,"Baxter Submits Application To Japan's MHLW For Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A",PRN15-Apr-15,NKTR-US,"Equities Updates on Pharma Industry -- Eli Lilly, Sanofi, AstraZeneca, Nektar Therapeutics, and BioDelivery Sciences Intl.",PRN13-Apr-15,NKTR-US,Nektar Therapeutics to Present at the 14th Annual Needham Healthcare Conference,PRN2-Apr-15,NKTR-US,Nektar Announces Receipt of $100 Million Milestone Payment from AstraZeneca,PRN31-Mar-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Needham & Company Health Care Conference for 15-April-2015 8:00 AM ET,FCSTTS31-Mar-15,NKTR-US,MOVANTIK™ (Naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain Launched In The US,PRN19-Mar-15,NKTR-US,AstraZeneca And Daiichi Sankyo To Jointly Commercialise MOVANTIK In The US,PRN18-Mar-15,NKTR-US,Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Nektar Therapeutics,PRN17-Mar-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules NKTR-102 Phase 3 Study Results Call for 17-March-2015 4:45 PM ET,FCSTTS17-Mar-15,NKTR-US,Etirinotecan Pegol (NKTR-102) Prolonged Median Overall Survival by 2.1 Months versus Active Control in Patients with Advanced Breast Cancer in Phase 3 Study; Trial Did Not Achieve Statistical Significance (p=0.08),PRN10-Mar-15,NKTR-US,"Technical Snapshot on Pharma Stocks -- Pfizer, Zogenix, Sanofi, Nektar Therapeutics, and IGI Laboratories",PRN25-Feb-15,NKTR-US,Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain,PRN24-Feb-15,NKTR-US,Nektar Therapeutics Reports Fourth Quarter and Year-End 2014 Financial Results,PRN17-Feb-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2014 Earnings Release for 24-February-2015 After Market Hours ET,FCSTTS17-Feb-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2014 Earnings Call for 24-February-2015 5:00 PM ET,FCSTTS17-Feb-15,NKTR-US,"Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2014 on Tuesday, February 24, 2015, After Close of U.S.-Based Financial Markets",PRN11-Feb-15,NKTR-US,"Baxter Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A",PRN13-Jan-15,NKTR-US,"Technical Coverage on Pharma Stocks - Hospira, Auxilium Pharma, Medicines, SciClone Pharma, and Nektar Therapeutics",PRN8-Jan-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules JP Morgan Health Care Conference - Q&A Breakout Session for 13-January-2015 2:30 PM ET,FCSTTS6-Jan-15,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules JP Morgan Health Care Conference for 13-January-2015 2:00 PM ET,FCSTTS6-Jan-15,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN15-Dec-14,NKTR-US,"Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis",PRN11-Dec-14,NKTR-US,Nektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of Etirinotecan Pegol (NKTR-102) in Patients with Advanced Breast Cancer,PRN9-Dec-14,NKTR-US,MOVENTIG® Approved In The European Union For Opioid-Induced Constipation,PRN1-Dec-14,NKTR-US,"Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A",PRN24-Nov-14,NKTR-US,FDA Grants QIDP Designation to Bayer's Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation,PRN20-Nov-14,NKTR-US,Nektar Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with a PARP Inhibitor in BRCA1-deficient Cancer Model,PRN6-Nov-14,NKTR-US,Nektar Therapeutics Reports Financial Results for the Third Quarter of 2014,PRN3-Nov-14,NKTR-US,"Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings",PRN30-Oct-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2014 Earnings Call for 6-November-2014 5:00 PM ET,FCSTTS30-Oct-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2014 Earnings Release for 6-November-2014 After Market Hours ET,FCSTTS30-Oct-14,NKTR-US,"Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets",PRN9-Oct-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Jefferies Global Healthcare Conference for 19-November-2014,FCSTTS8-Oct-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Brean Capital Life Sciences Summit for 24-November-2014,FCSTTS26-Sep-14,NKTR-US,Nektar Therapeutics Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation,PRN24-Sep-14,NKTR-US,"Active Equities to Watch in Pharma Industry - Pfizer, BioDelivery Sciences Intl., Repros Therapeutics, Catalent, and Nektar Therapeutics",PRN19-Sep-14,NKTR-US,"Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting",PRN16-Sep-14,NKTR-US,FDA Approves MOVANTIK™ (naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain,PRN21-Aug-14,NKTR-US,"Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients",PRN12-Aug-14,NKTR-US,"Pharma Equities Coverage -- Pfizer, BioDelivery Sciences Intl., The Medicines, Questcor Pharma, and Nektar Therapeutics",PRN31-Jul-14,NKTR-US,Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014,PRN22-Jul-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2014 Earnings Call for 31-July-2014 5:00 PM ET,FCSTTS22-Jul-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2014 Earnings Release for 31-July-2014 After Market Hours ET,FCSTTS22-Jul-14,NKTR-US,"Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets",PRN7-Jul-14,NKTR-US,"Technical Pulse on Pharma Stocks -- Research on Pfizer, Hospira, Endo Intl., and Nektar Therapeutics",PRN4-Jul-14,NKTR-US,"Appointments, Acquisitions, Study Results, and Technical Updates - Analyst Notes on Alere, AMRI, Anika Therapeutics, Nektar and Sangamo",PRN19-Jun-14,NKTR-US,Data Published in the New England Journal of Medicine Demonstrate that Naloxegol Improved Opioid-Induced Constipation in Chronic Pain Patients,PRN18-Jun-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Piper Jaffray Catalyst Symposium for 8-July-2014,FCSTTS12-Jun-14,NKTR-US,US FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING MU-OPIOID RECEPTOR ANTAGONIST (PAMORA) CLASS INCLUDING MOVANTIK,PRN11-Jun-14,NKTR-US,Nektar Therapeutics Stock Trading Halted Today; FDA Advisory Committee to Discuss Peripherally-Acting Opioid Receptor Antagonists,PRN1-Jun-14,NKTR-US,"Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, at 50th ASCO Meeting",PRN31-May-14,NKTR-US,Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin®-Refractory High-Grade Glioma Presented at 50th ASCO Meeting,PRN19-May-14,NKTR-US,"Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer",PRN16-May-14,NKTR-US,Nektar Therapeutics To Present at the UBS 2014 Global Healthcare Conference in New York City,PRN7-May-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract Number: 3082 for 1-June-2014 9:00 AM ET,FCSTTS7-May-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract Number: 2096 for 31-May-2014 2:15 PM ET,FCSTTS7-May-14,NKTR-US,Nektar Therapeutics Reports Financial Results for the First Quarter of 2014,PRN6-May-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Annual General Meeting for 25-June-2014,FCSTTS1-May-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2014 Earnings Call for 7-May-2014 5:00 PM ET,FCSTTS1-May-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2014 Earnings Release for 7-May-2014 After Market Hours ET,FCSTTS1-May-14,NKTR-US,"Nektar to Announce Financial Results for the First Quarter 2014 on Wednesday, May 7, 2014, After Close of U.S.-Based Financial Markets",PRN1-May-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules UBS Global Healthcare Conference for 20-May-2014 2:30 PM ET,FCSTTS9-Apr-14,NKTR-US,Nektar Reports Positive Preclinical Data for Two Oncology Programs at 2014 AACR,PRN4-Mar-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules ROTH Capital Partners Conference for 10-March-2014 2:30 PM ET,FCSTTS26-Feb-14,NKTR-US,Nektar Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results,PRN19-Feb-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2013 Earnings Call for 26-February-2014 5:00 PM ET,FCSTTS19-Feb-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2013 Earnings Release for 26-February-2014 After Market Hours ET,FCSTTS19-Feb-14,NKTR-US,"Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2013 on Wednesday, February 26, 2014, After Close of U.S.-Based Financial Markets",PRN22-Jan-14,NKTR-US,Nektar Therapeutics Prices Public Offering of Common Stock,PRN21-Jan-14,NKTR-US,"Nektar Therapeutics Announces Public Offering of 8,500,000 Shares of Common Stock",PRN18-Jan-14,NKTR-US,Nektar Presents Positive Clinical Data from a Phase 1 Study of Etirinotecan Pegol (NKTR-102) in Combination with 5-Flourouracil/Leucovorin at the 2014 Gastrointestinal Cancers Symposium,PRN16-Jan-14,NKTR-US,"Market Technicals Simplified: Inovio Pharma, Sequenom, Nektar Therapeutics, and Discovery Laboratories",PRN14-Jan-14,NKTR-US,Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer,PRN14-Jan-14,NKTR-US,"First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain",PRN8-Jan-14,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Healthcare Conference for 14-January-2014 1:00 PM ET,FCSTTS8-Jan-14,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN25-Dec-13,NKTR-US,"Addition to Indices, and Stock Price Movements - Research Report on ACADIA Pharmaceuticals, InterMune, Tandem Diabetes Care, Nektar Therapeutics and Greatbatch",PRN17-Dec-13,NKTR-US,"AAAResearchReports.com Pre-Market Technical Analysis: Inovio Pharma, Sequenom, Nektar Therapeutics, and Discovery Laboratories",PRN28-Nov-13,NKTR-US,"New Research Arrangements, Investor Conference Schedules, Reimbursement Agreements, and NDA Acceptances - Research Report on Quintiles, Insys, HeartWare, Given Imaging, and Nektar",PRN20-Nov-13,NKTR-US,"Financing, Special Reports, and Clinical Trial Updates - Research Report on PDL, DexCom, Quintiles, KYTHERA, and Nektar",PRN19-Nov-13,NKTR-US,"Morning Research: Inovio Pharma Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc.",PRN19-Nov-13,NKTR-US,New Drug Application For Naloxegol Accepted By United States Food And Drug Administration,PRN13-Nov-13,NKTR-US,"Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A",PRN12-Nov-13,NKTR-US,"Updates on Clinical Studies and Milestone Revenues - Research Report on Cyberonics, West, Nektar, OraSure, and Akorn",PRN7-Nov-13,NKTR-US,Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013,PRN30-Oct-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2013 Earnings Call for 7-November-2013 5:00 PM ET,FCSTEV30-Oct-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2013 Earnings Release for 7-November-2013 After Market Hours ET,FCSTEV30-Oct-13,NKTR-US,"Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets",PRN28-Oct-13,NKTR-US,"Today's Research: Inovio Pharmaceuticals Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc.",PRN24-Oct-13,NKTR-US,Nektar and Roswell Park Cancer Institute Announce Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Second-Line Treatment in Patients with Relapsed or Refractory Small Cell Lung Cancer (SCLC),PRN16-Oct-13,NKTR-US,"Dividend Announcements, Earnings Release Scheduled, and Data Presentations from Clinical Studies - Research Report on Questcor, Regeneron, NPS, Incyte, and Nektar",PRN8-Oct-13,NKTR-US,Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day,PRN7-Oct-13,NKTR-US,"Regulatory Approvals, Public Offerings and Clinical Trial Results - Research Report on Theravance, Synageva, Nektar, Clovis Oncology, and ImmunoGen",PRN3-Oct-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules R&D Day for 8-October-2013 11:30 AM ET,FCSTEV2-Oct-13,NKTR-US,Nektar to Host Investor and Analyst R&D Day in New York City,PRN2-Oct-13,NKTR-US,"Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations - Research Report on Celgene, Biogen Idec, Amgen, Nektar, and Zalicus",PRN30-Sep-13,NKTR-US,Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol,PRN26-Sep-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Phase 2 NKTR-181 Study Results Call for 26-September-2013 4:30 PM ET,FCSTEV26-Sep-13,NKTR-US,Nektar Announces Preliminary Topline Results from Phase 2 Efficacy Study for NKTR-181 in Chronic Pain Patients with Osteoarthritis of the Knee,PRN15-Aug-13,NKTR-US,"Pharma Companies Announce Investments in R&D, Ongoing Clinical Trials and Financial Results - Research Report on Alnylam, Infinity, Nektar, Sequenom, and Merrimack",PRN12-Aug-13,NKTR-US,"Wall Street Fundamentals Releases New In-Depth Stock Reports on DNDN, GERN, NKTR and NPSP",NEWS_ACW8-Aug-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules European Cancer Congress Conference for 30-September-2013 8:00 AM ET,FCSTEV8-Aug-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Chemical Society Meeting for 8-September-2013 7:00 PM ET,FCSTEV8-Aug-13,NKTR-US,Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013,PRN1-Aug-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2013 Earnings Call for 8-August-2013 5:00 PM ET,FCSTEV1-Aug-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2013 Earnings Release for 8-August-2013 After Market Hours ET,FCSTEV1-Aug-13,NKTR-US,"Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets",PRN30-Jul-13,NKTR-US,Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer,PRN19-Jun-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules NKTR-181 Study Results Call for 19-June-2013 1:00 PM ET,FCSTEV19-Jun-13,NKTR-US,"Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence",PRN3-Jun-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Annual Meeting - Abstract # 3060 for 3-June-2013 9:00 AM ET,FCSTEV3-Jun-13,NKTR-US,"Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting",PRN1-Jun-13,NKTR-US,Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting,PRN31-May-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Jefferies Global Healthcare Conference for 4-June-2013 9:00 AM ET,FCSTEV30-May-13,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City",PRN21-May-13,NKTR-US,Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013,BW16-May-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules UBS Global Healthcare Conference for 21-May-2013 10:00 AM ET,FCSTEV16-May-13,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City",PRN10-May-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Annual Meeting - Abstract Number: 1087 for 1-June-2013 2:15 PM ET,FCSTEV9-May-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Annual Meeting - Abstract Number: 3060 for 1-June-2013 9:00 AM ET,FCSTEV9-May-13,NKTR-US,Nektar Therapeutics Reports Financial Results for the First Quarter of 2013,PRN2-May-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2013 Earnings Release for 9-May-2013 After Market Hours ET,FCSTEV2-May-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2013 Earnings Call for 9-May-2013 5:00 PM ET,FCSTEV2-May-13,NKTR-US,"Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets",PRN29-Apr-13,NKTR-US,Technical Stock Breakout Watch: Nektar Therapeutics (NKTR),NEWS_ACW17-Apr-13,NKTR-US,"Critical Alerts For Intel, Delta, Southern Copper, Lam Research, and Nektar Therapeutics Released By InvestorsObserver",PRN16-Apr-13,NKTR-US,Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia,PRN7-Apr-13,NKTR-US,"Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013",PRN19-Mar-13,NKTR-US,New Programs Designed to Speed up Approval Process a Key Factor in Biotech Industry's Growth in 2012,INW8-Mar-13,NKTR-US,"Pushing Pipelines Forward for Long-Term Success - Research Report on Vertex, Santarus, Arena Pharmaceuticals, Seattle Genetics and Nektar Therapeutics",PRN5-Mar-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules ROTH Capital Partners Growth Stock Conference for 19-March-2013 3:30 PM ET,FCSTEV5-Mar-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Pain Society Scientific Meeting for 9-May-2013 9:30 AM ET,FCSTEV4-Mar-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract #2475 for 9-April-2013 8:00 AM ET,FCSTEV4-Mar-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Association for Cancer Research Meeting - Abstract #482 for 7-April-2013 1:00 PM ET,FCSTEV2-Mar-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Cowen & Company Healthcare Conference for 5-March-2013 8:00 AM ET,FCSTEV1-Mar-13,NKTR-US,Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston,PRN28-Feb-13,NKTR-US,Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results,PRN26-Feb-13,NKTR-US,AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation,PRN13-Feb-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2012 Earnings Call for 28-February-2013 5:00 PM ET,FCSTEV13-Feb-13,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2012 Earnings Release for 28-February-2013 After Market Hours ET,FCSTEV13-Feb-13,NKTR-US,"Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets",PRN7-Feb-13,NKTR-US,Number of FDA Drug Approvals Reach a 15-Year High in 2012,INW5-Feb-13,NKTR-US,Nektar Announces Initiation of Investigator-Initiated Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Third-Line Treatment in Patients with Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC),PRN23-Jan-13,NKTR-US,"The Real Story Behind AMBS, ARNA, NKTR and URS",INW16-Jan-13,NKTR-US,Record Levels of Available Cash and Moderate R&D Development Will See Big Pharma M&A Activity Increase in 2013,INW10-Jan-13,NKTR-US,"Our Pros Knew HMSY, NKTR, TTM and HSP Would Be Top Gainers on Wednesday ",INW10-Jan-13,NKTR-US,"The Real Story Behind NUVA, NKTR, HOLX and VOLC ",INW4-Jan-13,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN20-Dec-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules JP Morgan Healthcare Conference for 9-January-2013 11:30 AM ET,FCSTEV15-Nov-12,NKTR-US,"Research Reports on Top Stocks: Verizon, Nokia, CYS Investments, Prospect Capital, Huntington Bancshares, and Nektar Therapeutics",PRN13-Nov-12,NKTR-US,"Free Research Reports on ARRY, CECO, GILD and NKTR Issued by the Bedford Report ",INW12-Nov-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Jefferies Global Healthcare Conference for 14-November-2012 6:20 AM ET,FCSTEV12-Nov-12,NKTR-US,AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation,PRN12-Nov-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Naloxegol Pivotal Phase III Trial Results Call for 12-November-2012 8:15 AM ET,FCSTEV11-Nov-12,NKTR-US,Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol,PRN7-Nov-12,NKTR-US,Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer,PRN6-Nov-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2012 Earnings Release for 13-November-2012 After Market Hours ET,FCSTEV6-Nov-12,NKTR-US,"Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets",PRN15-Oct-12,NKTR-US,"Nektar Presents Positive Preclinical Data for NKTR-171, A Novel Sodium Channel Blocker to Treat Neuropathic Pain, at 41st Annual Meeting of the Society for Neuroscience",PRN1-Oct-12,NKTR-US,GreeneStone Muskoka Once Again Featured on Intervention Canada,BW18-Sep-12,NKTR-US,"NKTR-192, A New Short-Acting Mu-Opioid Analgesic Molecule, Achieves Desired Pharmacokinetic Profile in First Phase 1a Clinical Study",PRN13-Sep-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules UBS Global Life Sciences Conference for 19-September-2012 10:30 AM ET,FCSTEV13-Sep-12,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City",PRN9-Aug-12,NKTR-US,Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012,PRN7-Aug-12,NKTR-US,Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma,PRN2-Aug-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2012 Earnings Call for 9-August-2012 5:00 PM ET,FCSTEV2-Aug-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2012 Earnings Release for 9-August-2012 After Market Hours ET,FCSTEV2-Aug-12,NKTR-US,"Nektar to Announce Financial Results for the Second Quarter of 2012 On Thursday, August 9, 2012, After Close of U.S.-Based Financial Markets",PRN24-Jul-12,NKTR-US,"Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain",PRN10-Jul-12,NKTR-US,Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017,PRN7-Jun-12,NKTR-US,"Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain",PRN30-May-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Jefferies & Co Health Care Conference for 5-June-2012 11:30 AM ET,FCSTEV30-May-12,NKTR-US,Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York,PRN24-May-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology (ASCO) Meeting - Abstract: #5048/18H for 3-June-2012 9:00 AM ET,FCSTEV24-May-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Oncology (ASCO) Meeting - Abstract # TPS1140/36A for 2-June-2012 9:00 AM ET,FCSTEV18-May-12,NKTR-US,Fitch Affirms RPI Finance Trust's Ratings at 'BBB-',BW2-May-12,NKTR-US,Nektar Therapeutics Reports Financial Results for the First Quarter of 2012,PRN26-Apr-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Health Care Conference for 7-May-2012 4:50 PM ET,FCSTEV25-Apr-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2012 Earnings Call for 2-May-2012 5:00 PM ET,FCSTEV25-Apr-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2012 Earnings Release for 2-May-2012 After Market Hours ET,FCSTEV25-Apr-12,NKTR-US,"Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets",PRN10-Apr-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Investor and Analyst R&D Day for 16-April-2012 12:00 PM ET,FCSTEV10-Apr-12,NKTR-US,Nektar to Host Investor and Analyst R&D Day in New York City,PRN2-Apr-12,NKTR-US,"Nektar Doses First Subjects in Phase 1 Clinical Study Evaluating NKTR-192, a New Short-Acting Opioid Molecule for the Treatment of Acute Pain",PRN28-Mar-12,NKTR-US,Nektar Reports that Partner Affymax Has Announced FDA Approval of OMONTYS® (Peginesatide) Injection for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis,PRN20-Mar-12,NKTR-US,Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay,PRN5-Mar-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Cowen and Company Healthcare Conference for 6-March-2012 10:00 AM ET,FCSTEV2-Mar-12,NKTR-US,Nektar Therapeutics Announces Webcast of Presentation at the 32nd Annual Cowen and Company Healthcare Conference in Boston,PRN1-Mar-12,NKTR-US,"Top Stock Alerts for Day Traders: JDS Uniphase, Kinross Gold, PulteGroup, Nektar Therapeutics, and New Gold",PRN29-Feb-12,NKTR-US,Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results,PRN29-Feb-12,NKTR-US,Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million,PRN27-Feb-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2011 Earnings Call for 29-February-2012 5:00 PM ET,FCSTEV27-Feb-12,NKTR-US,"Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting",PRN24-Feb-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2011 Earnings Release for 29-February-2012 After Market Hours ET,FCSTEV24-Feb-12,NKTR-US,"Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2011 on Wednesday, February 29, 2012, After Close of U.S.-Based Financial Markets",PRN13-Jan-12,NKTR-US,"A Forward Look, the Year Ahead -- Featured Research on Achillion Pharmaceuticals, Inc. and Nektar Therapeutics ",INW5-Jan-12,NKTR-US,Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A,PRN5-Jan-12,NKTR-US,Baxter Initiates Phase I Clinical Trial of Longer-Acting Recombinant FVIII Treatment for Hemophilia A,BW4-Jan-12,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN3-Jan-12,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules JPMorgan Healthcare Conference for 11-January-2012 11:30 AM ET,FCSTEV13-Dec-11,NKTR-US,"Nektar Announces Positive Clinical Data from Second Phase 1 Clinical Study of NKTR-181, a Novel Opioid Analgesic Molecule to Treat Chronic Pain",PRN12-Dec-11,NKTR-US,Nektar Therapeutics Initiates Phase 3 BEACON Trial of NKTR-102 in Women with Metastatic Breast Cancer,PRN8-Dec-11,NKTR-US,Nektar Reports Affymax Announced FDA Advisory Committee Voted in Favor of Benefit/Risk Profile for Peginesatide for Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis,PRN15-Nov-11,NKTR-US,NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer,PRN14-Nov-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules AACR-NCI-EORTC International Conference for 15-November-2011 3:30 PM ET,FCSTEV14-Nov-11,NKTR-US,Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011,PRN2-Nov-11,NKTR-US,Nektar Therapeutics Reports Third Quarter 2011 Financial Results,PRN26-Oct-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2011 Earnings Call for 2-November-2011 5:00 PM ET,FCSTEV26-Oct-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2011 Earnings Release for 2-November-2011 After Market Hours ET,FCSTEV26-Oct-11,NKTR-US,"Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets",PRN14-Oct-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules BioCentury Newsmakers in the Biotech Industry Conference for 21-October-2011 10:30 AM ET,FCSTEV21-Sep-11,NKTR-US,"Nektar Presents Positive Data for Novel Opioid Analgesic, NKTR-181, at the 2011 American Academy of Pain Management Annual Meeting",PRN20-Sep-11,NKTR-US,"Global Situation & Resulting Influences - Research Report on Achillion Pharmaceuticals, Inc. and Nektar Therapeutics ",INW15-Sep-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules UBS Global Life Sciences Conference for 20-September-2011 10:00 AM ET,FCSTEV14-Sep-11,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City",PRN9-Sep-11,NKTR-US,Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium,PRN8-Sep-11,NKTR-US,"Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain",PRN8-Aug-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules ASCO Breast Cancer Symposium - Abstract #269 for 9-September-2011,FCSTEV4-Aug-11,NKTR-US,Nektar Therapeutics Reports Second Quarter 2011 Financial Results,PRN27-Jul-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2011 Earnings Call for 4-August-2011 5:00 PM ET,FCSTEV27-Jul-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2011 Earnings Release for 4-August-2011 After Market Hours ET,FCSTEV27-Jul-11,NKTR-US,"Nektar to Announce Financial Results for the Second Quarter of 2011 on Thursday, August 4, 2011, After Close of U.S.-Based Financial Markets",PRN25-Jul-11,NKTR-US,TARIS Appoints Christopher Searcy as the Company's Chief Business Officer,BW18-Jul-11,NKTR-US,NKTR-102 Receives Positive Opinion From EMA COMP for Orphan Medicinal Product Designation in Ovarian Cancer,PRN7-Jun-11,NKTR-US,Data from Phase 1 Study of NKTR-181 Demonstrate Proof-of-Concept for Nektar's Novel Opioid Analgesic Candidate,PRN5-Jun-11,NKTR-US,NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®,PRN4-Jun-11,NKTR-US,NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting,PRN1-Jun-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Jefferies & Co. Global Healthcare Conference for 7-June-2011 10:00 AM ET,FCSTEV1-Jun-11,NKTR-US,Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York,PRN19-May-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #5047 for 5-June-2011 9:00 AM ET,FCSTEV19-May-11,NKTR-US,"Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #2598, Poster Board: #8E for 6-June-2011 9:00 AM ET",FCSTEV19-May-11,NKTR-US,"Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology Meeting - Abstract #1034, Poster Board #24 for 4-June-2011 3:00 PM ET",FCSTEV19-May-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Investor and Analyst Meeting for 6-June-2011 8:30 AM ET,FCSTEV18-May-11,NKTR-US,Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting,PRN27-Apr-11,NKTR-US,Nektar Therapeutics Reports First Quarter 2011 Financial Results,PRN22-Apr-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Bank of America Merrill Lynch Health Care Conference for 12-May-2011 2:50 PM ET,FCSTEV21-Apr-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Health Care Conference for 2-May-2011 11:20 AM ET,FCSTEV21-Apr-11,NKTR-US,"FDA Grants Orphan Drug Designation for Nektar's Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer",PRN18-Apr-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2011 Earnings Release for 27-April-2011 After Market Hours ET,FCSTEV18-Apr-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2011 Earnings Call for 27-April-2011 5:00 PM ET,FCSTEV18-Apr-11,NKTR-US,"Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets",PRN21-Mar-11,NKTR-US,"Nektar Initiates Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Pain",PRN15-Mar-11,NKTR-US,AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation,PRN1-Mar-11,NKTR-US,Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results,PRN1-Mar-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Cowen and Company Health Care Conference for 8-March-2011 11:00 AM ET,FCSTEV1-Mar-11,NKTR-US,Nektar Therapeutics' President and CEO Howard W. Robin to Present at the 31st Annual Cowen and Company Healthcare Conference in Boston,PRN21-Feb-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Barclays Capital Global Healthcare Conference for 17-March-2011 8:30 AM ET,FCSTEV17-Feb-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2010 Earnings Call for 1-March-2011 5:00 PM ET,FCSTEV17-Feb-11,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2010 Earnings Release for 1-March-2011 After Market Hours ET,FCSTEV17-Feb-11,NKTR-US,"Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2010 on Tuesday, March 1, 2011, After Close of U.S.-Based Financial Markets",PRN24-Jan-11,NKTR-US,Nektar Therapeutics Completes Public Offering of Common Stock,PRN19-Jan-11,NKTR-US,Nektar Therapeutics Prices Public Offering of Common Stock,PRN18-Jan-11,NKTR-US,Nektar Therapeutics Announces Proposed Public Offering of Common Stock,PRN13-Jan-11,NKTR-US,"Zacks Sell List Highlights: FreightCar America, Brookfield Asset Management, Becton, Dickinson and Co. and Nektar Therapeutics",PRN5-Jan-11,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN22-Dec-10,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules J.P. Morgan Healthcare Conference for 11-January-2011 11:30 AM ET,FCSTEV12-Dec-10,NKTR-US,NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients,PRN9-Dec-10,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules AACR San Antonio Breast Cancer Symposium for 12-December-2010 10:00 AM ET,FCSTTS9-Dec-10,NKTR-US,Phase 2 Clinical Data on NKTR-102 in Metastatic Breast Cancer to Be Presented at 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium,PRN13-Nov-10,NKTR-US,Nektar Announces Two Preclinical Data Presentations at Society for Neuroscience 40th Annual Meeting: Neuroscience 2010,PRN4-Nov-10,NKTR-US,Nektar Therapeutics Reports Third Quarter 2010 Financial Results,PRN29-Oct-10,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2010 Earnings Call for 4-November-2010 5:00 PM ET,FCSTTS28-Oct-10,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2010 Earnings Release for 4-November-2010 After Market Hours ET,FCSTTS28-Oct-10,NKTR-US,"Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets",PRN17-Oct-10,NKTR-US,Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010,PRN15-Oct-10,NKTR-US,"NKTR-181, A Mu-Opioid Analgesic With a Novel Molecular Structure, Demonstrates Slower Entry Rate Into the Brain and Reduced CNS Side Effects",PRN17-Sep-10,NKTR-US,Nektar Therapeutics To Present at the UBS 2010 Global Life Sciences Conference,PRN15-Sep-10,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules UBS Global Life Sciences Conference for 21-September-2010 11:00 AM ET,FCSTTS31-Aug-10,NKTR-US,BioSpace Highlights Northern California's Growing Life Science Region,PRN28-Jul-10,NKTR-US,Nektar Therapeutics Reports Second Quarter 2010 Financial Results,PRN21-Jul-10,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2010 Earnings Call for 28-July-2010 5:00 PM ET,FCSTTS21-Jul-10,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2010 Earnings Release for 28-July-2010 After Market Hours ET,FCSTEV21-Jul-10,NKTR-US,"Nektar to Announce Financial Results for the Second Quarter of 2010 On Wednesday, July 28, 2010, After Close of U.S.-Based Financial Markets",PRN6-Jul-10,NKTR-US,NKTR-102 Demonstrates Superior Activity to Irinotecan in Nonclinical Studies Presented at ESMO 12th World Congress on Gastrointestinal Cancer,PRN24-Jun-10,NKTR-US,Nektar Announces Dosing of First Patients in Phase 1 Clinical Study of NKTR-102 in Combination With 5-Fluorouracil/Leucovorin,PRN9-Jun-10,NKTR-US,Nektar Therapeutics Announces Positive Initial Results from Phase 2 Study of NKTR-102 in Metastatic Breast Cancer,PRN7-Jun-10,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology for 7-June-2010 7:30 AM ET,FCSTTS6-Jun-10,NKTR-US,NKTR-102 Has High Response Rate and Sustained Clinical Benefit in 48 Percent of Women with Platinum-Resistant/Refractory Ovarian Cancer,PRN3-Jun-10,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Jefferies Global Life Sciences Conference for 9-June-2010 10:00 AM ET,FCSTTS3-Jun-10,NKTR-US,Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2010 Global Life Sciences Healthcare Conference in New York,PRN20-May-10,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Society of Clinical Oncology - NKTR-102 for 6-June-2010 12:15 PM ET,FCSTTS20-May-10,NKTR-US,NKTR-102 Phase 2 Clinical Data Accepted for Oral Presentation at 2010 ASCO Annual Meeting,PRN5-May-10,NKTR-US,Nektar Therapeutics Reports First Quarter 2010 Financial Results,PRN27-Apr-10,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2010 Earnings Call for 5-May-2010 5:00 PM ET,FCSTTS27-Apr-10,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2010 Earnings Release for 5-May-2010 After Market Hours ET,FCSTTS27-Apr-10,NKTR-US,"Nektar to Announce Financial Results for the First Quarter of 2010 on Wednesday, May 5, 2010, After Close of U.S.-Based Financial Markets",PRN8-Mar-10,NKTR-US,Nektar Announces Positive Phase 2 Clinical Data from First Stage of NKTR-102 Study in Women with Platinum-Resistant Ovarian Cancer,PRN3-Mar-10,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Cowen & Company Health Care Conference for 8-March-2010 1:00 PM ET,FCSTTS2-Mar-10,NKTR-US,Nektar Therapeutics' President and CEO Howard W. Robin to Present at the 30th Annual Cowen and Company Healthcare Conference in Boston,PRN2-Mar-10,NKTR-US,Nektar Therapeutics Reports Year-End 2009 Financial Results,PRN24-Feb-10,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2009 Earnings Call for 2-March-2010 5:00 PM ET,FCSTTS23-Feb-10,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2009 Earnings Release for 2-March-2010 After Market Hours ET,FCSTTS23-Feb-10,NKTR-US,"Nektar to Announce Year-End 2009 Financial Results on Tuesday, March 2, 2010, After Close of U.S.-Based Financial Markets",PRN2-Feb-10,NKTR-US,Nektar Therapeutics Appoints R. Scott Greer to Board of Directors,PRN14-Jan-10,NKTR-US,"Aggressive Traders Alert: Wound Management Technologies -- January 14, 2010 ",INW12-Jan-10,NKTR-US,Nektar Therapeutics Announces Positive Topline Results for NKTR-102 From First Stage of Phase 2 Study in Platinum-Resistant Ovarian Cancer,PRN11-Jan-10,NKTR-US,Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors,PRN6-Jan-10,NKTR-US,"Nektar Therapeutics Names Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Scientific Officer",PRN6-Jan-10,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco, CA",PRN29-Dec-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules JPMorgan Healthcare Conference for 12-January-2010 1:00 PM ET,FCSTEV14-Dec-09,NKTR-US,Dennis Winger Joins Nektar Therapeutics' Board of Directors,PRN30-Nov-09,NKTR-US,"Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer",PRN4-Nov-09,NKTR-US,Nektar Therapeutics Reports Third Quarter 2009 Financial Results,PRN29-Oct-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2009 Earnings Release for 4-November-2009 After Market Hours ET,FCSTEV29-Oct-09,NKTR-US,"Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets",PRN29-Oct-09,NKTR-US,"Alexandria Real Estate Equities, Inc. Provides Update",PRN28-Oct-09,NKTR-US,Nektar Completes Enrollment Ahead of Schedule in Phase 2 Clinical Trial Evaluating NKTR-102 in Patients with Platinum-Resistant Ovarian Cancer,PRN27-Oct-09,NKTR-US,Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego,PRN26-Oct-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2009 Earnings Call for 4-November-2009 5:00 PM ET,FCSTEV10-Oct-09,NKTR-US,Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix,PRN22-Sep-09,NKTR-US,Nektar Therapeutics (NKTR) President and Chief Executive Officer to Ring The NASDAQ Stock Market Closing Bell,PMZ22-Sep-09,NKTR-US,NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress,PRN21-Sep-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Business Update Call for 21-September-2009 8:30 AM ET,FCSTEV21-Sep-09,NKTR-US,Nektar Therapeutics to Host Conference Call to Discuss Today's Announcement of a New Partnership for NKTR-118 and NKTR-119,PRN21-Sep-09,NKTR-US,AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation,PRN18-Sep-09,NKTR-US,Nektar Therapeutics to Present at the UBS 2009 Global Life Sciences Conference in New York City,PRN13-Sep-09,NKTR-US,Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118,PRN10-Sep-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules UBS Global Life Sciences Conference for 22-September-2009 10:30 AM ET,FCSTEV5-Aug-09,NKTR-US,"International Tower Hill Delineates Major New Zone of Gold Mineralization at Livengood Gold Project, Alaska",INW4-Aug-09,NKTR-US,Nektar Therapeutics Reports Second Quarter 2009 Financial Results,PRN4-Aug-09,NKTR-US,"International Tower Hill Mines Signs Agreement to Acquire 100% Interest in North Bullfrog Project, Nevada",INW2-Aug-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules BMO Capital Markets Focus on Healthcare Conference for 5-August-2009 1:45 PM ET,FCSTEV31-Jul-09,NKTR-US,Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City,PRN31-Jul-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2009 Earnings Call for 4-August-2009 5:00 PM ET,FCSTEV31-Jul-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2009 Earnings Release for 4-August-2009 After Market Hours ET,FCSTEV31-Jul-09,NKTR-US,"Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets",PRN20-Jul-09,NKTR-US,"International Tower Hill Announces Results for First 16 Holes of Summer 2009 Drill Program at Livengood Gold Deposit, Alaska",INW10-Jul-09,NKTR-US,International Tower Hill Receives Share Ownership Top-Up Notice From AngloGold Ashanti,INW30-Jun-09,NKTR-US,International Tower Hill Mines Retains Renmark Financial Communications Inc.,INW26-Jun-09,NKTR-US,"Free Growth Strategy Report on MELI, CBST, NKTR, IVAN, SBIB and REXX by MaybachFinancial.com",INW25-Jun-09,NKTR-US,"International Tower Hill Announces Resource Update at Livengood, Alaska",INW10-Jun-09,NKTR-US,"International Tower Hill Mines Livengood Gold Project, Alaska",INW9-Jun-09,NKTR-US,"Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer",PRN1-Jun-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Annual General Meeting for 11-June-2009 5:00 PM ET,FCSTEV15-May-09,NKTR-US,"TheFortuneFinancial.com Initializes Free Analyst Research on NKTR, DPTR, NCMI and INSM",INW14-May-09,NKTR-US,Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis,PRN13-May-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Healthcare Conference for 18-May-2009 1:45 PM ET,FCSTEV12-May-09,NKTR-US,Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston,PRN12-May-09,NKTR-US,"International Tower Hill Announces Latest Winter Program Drill Results From NE and SW Zones, Livengood Gold Deposit, Alaska",INW6-May-09,NKTR-US,Nektar Therapeutics Reports First Quarter 2009 Financial Results,PRN30-Apr-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2009 Earnings Call for 6-May-2009 5:00 PM ET,FCSTEV29-Apr-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2009 Earnings Release for 6-May-2009 After Market Hours ET,FCSTEV29-Apr-09,NKTR-US,"Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets",PRN23-Apr-09,NKTR-US,"International Tower Hill Reports Extension of High Grade SW Zone and Expansion of Livengood Gold Deposit, Alaska",INW22-Apr-09,NKTR-US,NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR,PRN15-Apr-09,NKTR-US,International Tower Hill's Livengood Project Returns 89% Gold Recovery From Recent Metallurgical Testwork,INW2-Apr-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference for 2-April-2009 11:00 AM ET,FCSTEV12-Mar-09,NKTR-US,Steve Aaker Joins the Board of Directors of International Tower Hill Mines Ltd.,INW10-Mar-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Cowen & Co. Health Care Conference for 16-March-2009 2:25 PM ET,FCSTEV10-Mar-09,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston",PRN10-Mar-09,NKTR-US,"International Tower Hill Mines Ltd. Doubles Planned 2009 Drill Program for Livengood Gold Project, Alaska",INW4-Mar-09,NKTR-US,"International Tower Hill Mines Ltd. Closes $10,500,000 Bought Deal Equity Financing",INW2-Mar-09,NKTR-US,Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC),PRN24-Feb-09,NKTR-US,Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results,PRN17-Feb-09,NKTR-US,Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors,PRN12-Feb-09,NKTR-US,International Tower Hill Mines Ltd. Announces Bought Deal Equity Financing,INW11-Feb-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2008 Earnings Release for 24-February-2009,FCSTEV11-Feb-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2008 Earnings Call for 2-March-2009 5:00 PM ET,FCSTEV11-Feb-09,NKTR-US,"Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets",PRN9-Feb-09,NKTR-US,"International Tower Hill Mines Livengood Gold Project, Alaska",INW29-Jan-09,NKTR-US,Nektar Announces Retirement of Irwin Lerner from Board of Directors,PRN28-Jan-09,NKTR-US,"International Tower Hill Mines Livengood Gold Project, Alaska",INW13-Jan-09,NKTR-US,First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer,PRN13-Jan-09,NKTR-US,International Tower Hill Continues to Expand Livengood Gold Deposit,INW5-Jan-09,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules JP Morgan Healthcare Conference for 13-January-2009 1:00 PM ET,FCSTEV5-Jan-09,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco",PRN31-Dec-08,NKTR-US,Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million,PRN31-Dec-08,NKTR-US,Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million,PRN10-Dec-08,NKTR-US,International Tower Hill Mines Ltd.: Livengood Gold Deposit Expands in all Directions,INW1-Dec-08,NKTR-US,"ITH Discovers New High-grade Gold Mineralization on West Pogo Project, Alaska",INW25-Nov-08,NKTR-US,"ITH & Redstar Gold Increase Holdings at North Bullfrog Project, Nevada",INW17-Nov-08,NKTR-US,ITH's Multi-Million Ounce Livengood Gold Deposit Expanded by Step Out Drilling,INW6-Nov-08,NKTR-US,Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results,PRN4-Nov-08,NKTR-US,ITH Expands Chisna Porphyry Copper-Gold Belt With Multiple New Discoveries,INW29-Oct-08,NKTR-US,"ITH Doubles Gold Resource at Livengood Project, Alaska",INW27-Oct-08,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules R&D Day for 12-November-2008 12:00 PM ET,FCSTEV27-Oct-08,NKTR-US,Nektar Therapeutics to Webcast R&D Day on November 12th,PRN24-Oct-08,NKTR-US,Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium,PRN23-Oct-08,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2008 Earnings Release for 6-November-2008 After Market Hours ET,FCSTEV23-Oct-08,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2008 Earnings Call for 6-November-2008 5:00 PM ET,FCSTEV23-Oct-08,NKTR-US,"Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets",PRN23-Oct-08,NKTR-US,"Technical Trade Alerts on Market Movers: AAPL, ICOG, NKTR, STSI, HA, AVGN",NEWS_ACW23-Oct-08,NKTR-US,"Beacon Equity Issues Technical Trade Alerts on Market Movers: AAPL, ICOG, NKTR, STSI, HA, AVGN",PRN23-Oct-08,NKTR-US,Positive Preclinical Data Demonstrating Anti-Tumor Activity of NKTR-105 (PEG-docetaxel) Presented at 20th EORTC-NCI-AACR Conference,PRN21-Oct-08,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Acquisition of Novartis AG by Nektar Therapeutics Call for 21-October-2008 10:30 AM ET,FCSTEV21-Oct-08,NKTR-US,"Beacon Equity Issues Technical Trade Alerts on Market Movers: INCY, DRRX, MDRX, NKTR, PRGN, AFFX",PRN20-Oct-08,NKTR-US,"Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder",PRN20-Oct-08,NKTR-US,"ITH Defines High-Grade Surface Copper-Gold Anomalies at BMP Project, Alaska",INW20-Oct-08,NKTR-US,"Beacon Equity Issues Technical Trade Alerts on Market Movers: MFGD, LGDI, NGAS, SOLR, IILG, NKTR",PRN10-Oct-08,NKTR-US,"Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes",PRN7-Oct-08,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Natixis Bleichroeder Hidden Gems Conference for 13-October-2008 2:30 PM ET,FCSTEV7-Oct-08,NKTR-US,Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City,PRN30-Sep-08,NKTR-US,Multiple Gold Intersections Expand ITH's Livengood Deposit,INW16-Sep-08,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules UBS Global Life Science Conference for 23-September-2008 10:30 AM ET,FCSTEV16-Sep-08,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City",PRN4-Sep-08,NKTR-US,International Tower Hill Mines Ltd.: Livengood Deposit Significantly Expands High Grade Core Zones,INW2-Sep-08,NKTR-US,"ITH Announces Initial Resource Estimate for Mayflower Deposit at North Bullfrog Project, Nevada",INW6-Aug-08,NKTR-US,"Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer",PRN6-Aug-08,NKTR-US,Nektar Therapeutics Announces Second Quarter 2008 Results,PRN31-Jul-08,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2008 Earnings Call for 6-August-2008 5:00 PM ET,FCSTEV30-Jul-08,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2008 Earnings Release for 6-August-2008 After Market Hours ET,FCSTEV30-Jul-08,NKTR-US,"Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets",PRN23-Jul-08,NKTR-US,"ITH Intersects Additional Bulk-Tonnage-Grade Gold Intercepts at Livengood Deposit, Alaska",INW15-Jul-08,NKTR-US,International Tower Hill Amends Options,INW26-Jun-08,NKTR-US,"ITH Drills 202.69 Metres of 1.37 g/t Gold at Livengood Deposit, Alaska",INW17-Jun-08,NKTR-US,"Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes",PRN10-Jun-08,NKTR-US,"ITH Acquires 100% Interest in the Terra and LMS Projects, Alaska from AngloGold Ashanti Exploration (U.S.A.) Inc.",INW2-Jun-08,NKTR-US,Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan),PRN2-Jun-08,NKTR-US,"New Positive Data Announced for NKTR-102 (PEG-irinotecan), Highlights Promise of Nektar's Innovative Small Molecule PEG-Oncolytics",PRN30-May-08,NKTR-US,"Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)",PRN27-May-08,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules NKTR-102 Phase 1 Trial Results Call for 2-June-2008 7:30 PM ET,FCSTEV27-May-08,NKTR-US,"ITH Expands Mayflower Deposit at North Bullfrog Project, Nevada",INW22-May-08,NKTR-US,Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit,PRN19-May-08,NKTR-US,Amikacin Inhale Shows Promising Results in Phase II Study,PRN16-May-08,NKTR-US,Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings,PRN13-May-08,NKTR-US,"ITH Outlines Large Geophysical Anomalies Associated With High Copper-Gold-Silver Mineralization on BMP Project, Alaska",INW12-May-08,NKTR-US,"Nektar's PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress",PRN12-May-08,NKTR-US,"ITH Commences 42,000 Metre Resource Drilling Program at the Livengood Gold Project, Alaska",INW7-May-08,NKTR-US,Nektar Therapeutics Announces First Quarter 2008 Results,PRN7-May-08,NKTR-US,Nektar Receives Patent Covering Pulmonary Targeted Antibiotics,PRN7-May-08,NKTR-US,NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting,PRN30-Apr-08,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2008 Earnings Release for 7-May-2008 After Market Hours ET,FCSTEV30-Apr-08,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2008 Earnings Call for 7-May-2008 5:00 PM ET,FCSTEV30-Apr-08,NKTR-US,"Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets",PRN29-Apr-08,NKTR-US,"ITH Intersects New Zone of Mineralization at its North Bullfrog Project, Nevada",INW23-Apr-08,NKTR-US,FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform,PRN14-Apr-08,NKTR-US,"BellwetherReport.com Initiates Analyst Coverage on CPHD, STSA, CYTR and NKTR",INW14-Apr-08,NKTR-US,ITH Discovers Bulk Tonnage Gold System in Nevada,INW14-Apr-08,NKTR-US,Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting,PRN10-Apr-08,NKTR-US,Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings,PRN9-Apr-08,NKTR-US,"BellwetherReport.com Free Analyst Review for NKTR, MNKD, EPMD and AMGI",INW9-Apr-08,NKTR-US,"ITH Sells Interest in South Estelle Project, Alaska to Millrock Resources Inc.",INW9-Apr-08,NKTR-US,Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients,PRN26-Mar-08,NKTR-US,"ITH Acquires Strategic Base Metals Property Adjoining BMP Project, Alaska",INW20-Mar-08,NKTR-US,QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised),PRN19-Mar-08,NKTR-US,QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes,PRN27-Feb-08,NKTR-US,Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results,PRN21-Feb-08,NKTR-US,"Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets",PRN18-Feb-08,NKTR-US,"ITH Reports Multi-Million Ounce Inferred Gold Resource at Livengood Project, Alaska",INW13-Feb-08,NKTR-US,"ITH Reports Initial Inferred Gold Resource at LMS Project, Alaska",INW12-Feb-08,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2007 Earnings Call for 27-February-2008 5:00 PM ET,FCSTEV12-Feb-08,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2007 Earnings Release for 27-February-2008,FCSTEV12-Feb-08,NKTR-US,Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization,PRN12-Feb-08,NKTR-US,"Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Company's Board of Directors",PRN7-Feb-08,NKTR-US,"ITH Reports Initial Inferred Resource at Terra Project, Alaska",INW30-Jan-08,NKTR-US,"Nektar Therapeutics(NKTR-US) Schedules Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference for 5-February-2008 1:00 PM ET",FCSTEV29-Jan-08,NKTR-US,"Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City",PRN29-Jan-08,NKTR-US,ITH Outlines Planned US$11M Exploration Program For 2008,INW16-Jan-08,NKTR-US,ITH Grants Incentive Stock Options,INW8-Jan-08,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules JP Morgan Chase & Co Healthcare Conference for 8-January-2008 4:30 PM ET,FCSTEV8-Jan-08,NKTR-US,"ITH Defines New Surface Gold Targets and Progresses Toward First Resource Calculation on LMS Project, Alaska",INW8-Jan-08,NKTR-US,Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer,PRN8-Jan-08,NKTR-US,Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction,PRN7-Jan-08,NKTR-US,Baxter Announces Recombinant Factor IX Development Program For Hemophilia B,PRN2-Jan-08,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules JP Morgan Chase & Co Healthcare Conference for 8-January-2008 7:30 PM ET,FCSTEV2-Jan-08,NKTR-US,Nektar Therapeutics' President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference,PRN20-Dec-07,NKTR-US,Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia,PRN11-Dec-07,NKTR-US,Nektar Promotes John Nicholson to Serve as Chief Financial Officer,PRN10-Dec-07,NKTR-US,"ITH Acquires High-Grade Gold Vein System Adjacent to Its North Bullfrog Project, Nevada",INW29-Nov-07,NKTR-US,"International Tower Hill Mines Ltd.: Trenching Intersects High-Grade Gold Veins on Coffee Dome Project, Alaska",INW28-Nov-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Bank of Montreal Focus on Healthcare Conference for 5-December-2007 10:30 AM ET,FCSTEV28-Nov-07,NKTR-US,Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference,PRN27-Nov-07,NKTR-US,ITH Expands SE Chisna Porphyry Copper-Gold Target,INW16-Nov-07,NKTR-US,ITH's Livengood Gold Deposit Continues to Grow; Step-Out Drilling Dramatically Expands Bulk Tonnage Potential,INW15-Nov-07,NKTR-US,ITH Discovers Gold Endowed Vein System at Painted Hills Project in Nevada,INW14-Nov-07,NKTR-US,Nektar's Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York,PRN13-Nov-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules R&D Day for 14-November-2007 12:00 PM ET,FCSTEV13-Nov-07,NKTR-US,Nektar Therapeutics to Webcast R&D Day on November 14th,PRN13-Nov-07,NKTR-US,Pfizer and Nektar Reach Agreement on Exubera(R),PRN8-Nov-07,NKTR-US,"ITH Expands Terra High-Grade Gold Project, Alaska",INW7-Nov-07,NKTR-US,Nektar Therapeutics Announces Third Quarter 2007 Financial Results,PRN31-Oct-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2007 Earnings Call for 7-November-2007 5:00 PM ET,FCSTEV31-Oct-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2007 Earnings Release for 7-November-2007 After Market Hours ET,FCSTEV31-Oct-07,NKTR-US,"Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets",PRN25-Oct-07,NKTR-US,NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models,PRN19-Oct-07,NKTR-US,"Market Pulse Announces Its Hot Stock Alerts for Friday, October 19, 2007: PEP, DELL, ORCL, NKTR",INW18-Oct-07,NKTR-US,Nektar Therapeutics Issues Statement on Exubera,PRN18-Oct-07,NKTR-US,ITH Further Defines Mineralization at South Estelle,INW10-Oct-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules AACR-NCI-EORTC International Conference for 25-October-2007 8:30 PM ET,FCSTEV10-Oct-07,NKTR-US,Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference,PRN2-Oct-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Biotechnology Industry Organization Investor Forum for 10-October-2007 1:15 PM ET,FCSTEV2-Oct-07,NKTR-US,Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum,PRN27-Sep-07,NKTR-US,"ITH Continues to Significantly Expand Sediment Hosted Mineralization at Livengood Gold Deposit, Alaska",INW27-Sep-07,NKTR-US,NKTR-102 (PEG-Irinotecan) Demonstrates Significant Anti-Tumor Activity and Improved Pharmacokinetic Profile in Preclinical Studies Presented at ECCO,PRN26-Sep-07,NKTR-US,Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting,PRN24-Sep-07,NKTR-US,"ITH Reports Continued High-Grade Gold Intersections from Terra Project, Alaska",INW18-Sep-07,NKTR-US,"ITH Reports Initial Drilling Results at West Tanana Project, Central Alaska",INW18-Sep-07,NKTR-US,Nektar Therapeutics Creates New PEGylation and Pulmonary Research Units to Drive Innovative Technology-Based Product Pipeline,PRN13-Sep-07,NKTR-US,"ITH Begins Drilling on Painted Hills Project in Nevada, Early Encouraging Results",INW13-Sep-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules UBS Global Life Sciences Conference for 26-September-2007 11:00 AM ET,FCSTEV13-Sep-07,NKTR-US,Nektar Therapeutics President and CEO Howard Robin to Present at 2007 UBS Global Life Sciences Conference,PRN11-Sep-07,NKTR-US,"ITH Discovers New Copper-Gold Porphyry System on Its Chisna Project, Alaska",INW10-Sep-07,NKTR-US,Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting,PRN6-Sep-07,NKTR-US,Pearl Therapeutics Raises $15.5 Million in Private Financing,PRN5-Sep-07,NKTR-US,"ITH Reports Initial Drilling Results from its North Bullfrog Project, Nevada",INW29-Aug-07,NKTR-US,Nektar Therapeutics Appoints Lutz Lingnau as New Board Member,PRN23-Aug-07,NKTR-US,Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer,PRN8-Aug-07,NKTR-US,Nektar Therapeutics Announces Second Quarter 2007 Financial Results,PRN6-Aug-07,NKTR-US,Bayer HealthCare and Nektar Therapeutics Launch Global Development and Commercialization Agreement to Fight Gram-Negative Pneumonias,PRN1-Aug-07,NKTR-US,"ITH Discovers New Sediment Hosted High-Grade Gold Mineralization at Livengood Project, Alaska",INW31-Jul-07,NKTR-US,"ITH to Begin Trading on the AMEX on August 3, 2007",INW26-Jul-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules European Cancer Conference for 27-September-2007 2:00 AM ET,FCSTEV26-Jul-07,NKTR-US,Anti-Tumor Activity and Pharmacokinetic Properties of NKTR-102 (PEG-irinotecan) to be Presented at Upcoming Oncology Meeting,PRN26-Jul-07,NKTR-US,First Peer-Reviewed Preclinical and Early Phase 1 Results for NKTR-118 (oral PEG-naloxol) to be Presented at Upcoming Pharmacology and Pain Management Meetings,PRN25-Jul-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2007 Earnings Release for 8-August-2007 After Market Hours ET,FCSTEV25-Jul-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2007 Earnings Call for 8-August-2007 5:00 PM ET,FCSTEV25-Jul-07,NKTR-US,"Nektar to Announce Second Quarter 2007 Financial Results on Wednesday, August 8, 2007, After the Close of U.S. Financial Markets",PRN21-Jun-07,NKTR-US,ITH Completes Airborne Survey at Chisna Cu-Au Project,INW19-Jun-07,NKTR-US,ITH Signs Option Agreement to Earn Interest in New High-Grade Alaskan Gold Project,INW14-Jun-07,NKTR-US,"ITH Expands New High Grade Gold Zones with Ongoing Drill Program at its Bulk Tonnage Livengood Project, Alaska",INW12-Jun-07,NKTR-US,"ITH Begins Drilling Programs at Terra and West Tanana Projects, Alaska",INW6-Jun-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Annual Shareholder Meeting for 7-June-2007 4:00 PM ET,FCSTEV1-Jun-07,NKTR-US,(OTC: TFZP) Introduces Automated Hydration Equipment for High Volume Perishable Shipping,INW25-May-07,NKTR-US,Nektar Therapeutics President and CEO Howard Robin to Present at Bank of America 2007 Health Care Conference,BW24-May-07,NKTR-US,Ronald Sheardown and Michael Bartlett Join Board of Directors,INW24-May-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules PEGylation and Pulmonary Drug Development Update Call for 24-May-2007 9:00 AM ET,FCSTEV23-May-07,NKTR-US,CORRECTING and REPLACING Nektar Announces New Organizational Structure and Spending Reduction Initiatives to Solidify the Company's Leadership Position in PEGylation and Pulmonary Drug Development,BW22-May-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Banc of America Healthcare Conference for 31-May-2007 7:40 PM ET,FCSTEV21-May-07,NKTR-US,Nektar Threraputics Announces Phase 2a Clinical Results Regarding the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative Hospital-Acquired Pneumonia Presented at the Annual American Thoracic Society International Conference<>Pulmonary Antibiotics Platform for Ventilated Patients with Hospital Acquired Pneumonia. (Graphic: Business Wire),BW17-May-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules American Thoracic Society International Conference for 21-May-2007 11:15 AM ET,FCSTEV11-May-07,NKTR-US,(OTC: GNLM) Announced Stock Split Record Date,INW10-May-07,NKTR-US,"ITH Closes $2,880,000 Non-Brokered Private Placement",INW10-May-07,NKTR-US,"ITH Closes $14,650,800 Brokered Private Placement",INW9-May-07,NKTR-US,Nektar Therapeutics Announces First Quarter 2007 Results,BW9-May-07,NKTR-US,Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be Presented at American Thoracic Society International Conference,BW27-Apr-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Morgan Stanley Global Healthcare Conference for 3-May-2007 1:30 PM ET,FCSTEV27-Apr-07,NKTR-US,Nektar Executives Participating In Upcoming Investor Conferences,BW26-Apr-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2007 Earnings Call for 9-May-2007 4:30 PM ET,FCSTEV24-Apr-07,NKTR-US,"Nektar to Announce First Quarter 2007 Financial Results On Wednesday, May 9, 2007, After the Close of U.S. Financial Markets",BW19-Apr-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Securities Health Care Conference for 2-May-2007 1:00 PM ET,FCSTEV16-Apr-07,NKTR-US,"International Tower Hill Mines Ltd. Increases Brokered Private Placement to $14,650,800",INW12-Apr-07,NKTR-US,ITH Announces the Beginning of Drilling at Livengood and Outlines USD7M North American Exploration Program for 2007,INW11-Apr-07,NKTR-US,"International Tower Hill Mines Ltd. Negotiates $2,880,000 Non-Brokered Private Placement",INW10-Apr-07,NKTR-US,"International Tower Hill Mines Ltd. Negotiates $9,600,000 Brokered Private Placement",INW9-Apr-07,NKTR-US,Innovative Pulmonary and PEGylation-Based Therapeutic Product Development Drives Business Strategy of Nektar Therapeutics,BW5-Apr-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules CIBC Biotechnology & Specialty Pharmaceuticals Conference for 11-April-2007 11:30 AM ET,FCSTEV4-Apr-07,NKTR-US,CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference to Webcast Nektar Corporate Presentation,BW16-Mar-07,NKTR-US,ITH Signs Option Agreements to Earn Interests in Two Gold Projects in Nevada,INW13-Mar-07,NKTR-US,Nektar Initiates Phase 1 Clinical Program Evaluating NKTR-102 (PEG-irinotecan) for Potential to Treat Patients with Refractory Solid Tumors,BW13-Mar-07,NKTR-US,"ITH Acquires Key Land Position on Its Coffee Dome Project, Alaska and Dramatically Expands Its Gold Soil Anomaly",INW7-Mar-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Lehman Global Healthcare Conference for 20-March-2007 1:30 PM ET,FCSTEV7-Mar-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Cowen and Company Health Care Conference for 13-March-2007 2:30 PM ET,FCSTEV7-Mar-07,NKTR-US,Nektar to Present at Cowen & Company and Lehman Brothers Conferences,BW28-Feb-07,NKTR-US,Nektar Announces Financial Results for the Year and Fourth Quarter 2006,BW17-Feb-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2007 Earnings Release for 9-May-2007 After Market Hours ET,FCSTEV14-Feb-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2006 Earnings Call for 28-February-2007 5:00 PM ET,FCSTEV14-Feb-07,NKTR-US,Nektar Sets Announcement Date and Conference Call for Year End and Fourth Quarter 2006,BW2-Feb-07,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Merrill Lynch Global Pharmaceutical Biotechnology & Medical Device Conference for 7-February-2007 1:00 PM ET,FCSTEV1-Feb-07,NKTR-US,"Merrill Lynch 2007 Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Nektar Corporate Presentation",BW26-Jan-07,NKTR-US,"ITH Continues to Expand LMS Deposit, Alaska",INW23-Jan-07,NKTR-US,"ITH Intercepts New High Grade Gold Zone at its Bulk Tonnage Livengood Project, Alaska",INW8-Jan-07,NKTR-US,Nektar Appoints Howard W. Robin President and CEO,BW14-Dec-06,NKTR-US,Nektar Reports That Court Denies Novo Nordisk's Motion for Preliminary Injunction Against Exubera,BW7-Dec-06,NKTR-US,"ITH Discovers Bulk Tonnage Porphyry Related Gold System at its Blackshell Project, Alaska",INW28-Nov-06,NKTR-US,Advisory: BMO Capital Markets Focus on Healthcare Conference to Webcast Nektar Corporate Presentation,BW27-Nov-06,NKTR-US,ITH Defines New Copper-Gold-Silver System with Bulk Tonnage Potential on its Chisna Project in Alaska,INW16-Nov-06,NKTR-US,"ITH Intersects 4.2 Metres of 22.3 g/t Gold on Major Extension of the Vein System on the Terra Project, Alaska",INW9-Nov-06,NKTR-US,"ITH Confirms Presence of a Major Gold Target on its West Tanana Project, Alaska",INW2-Nov-06,NKTR-US,Nektar Announces Third Quarter 2006 Financial Results,BW1-Nov-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules CIBC Healthcare Conference for 7-November-2006 10:20 AM ET,FCSTEV1-Nov-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Lehman Brothers Small Cap Conference for 17-November-2006 12:20 PM ET,FCSTEV1-Nov-06,NKTR-US,"Nektar to Present at Three Conferences: Cowen & Company 7th Annual Global Health Care Conference, CIBC 17th Annual Healthcare Conference and Lehman Brothers Small Cap Conference",BW21-Oct-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2006 Earnings Release for 28-February-2007 After Market Hours ET,FCSTEV19-Oct-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2006 Earnings Call for 2-November-2006 5:00 PM ET,FCSTEV19-Oct-06,NKTR-US,Advisory: Nektar Sets Announcement Date and Conference Call for the Third Quarter 2006,BW11-Oct-06,NKTR-US,"ITH Consolidates Livengood Gold Project, Alaska Tests Bulk Tonnage Potential With 2500m Diamond Drillhole Program",INW3-Oct-06,NKTR-US,Nektar Therapeutics Issues Statement on Whistle-Blower Proceeding Status,BW3-Oct-06,NKTR-US,A Sarbanes-Oxley Whistleblower Action Against Nektar Therapeutics -- NKTR,INW29-Sep-06,NKTR-US,"ITH drilling Intersects 1540 g/t '49.5 ounces/t' Gold over 0.8 Metres at the LMS Project, Alaska",INW27-Sep-06,NKTR-US,International Tower Hill Mines Ltd.: 2006 Annual Meeting Results,INW24-Sep-06,NKTR-US,Complete Auto (OTC PK: ECFL) Trained by eBay Motors,INW21-Sep-06,NKTR-US,CORRECTING and REPLACING Zelos and Nektar Announce Start of Phase 1 Trial of Inhaled Ostabolin-C(TM) for Osteoporosis,BW18-Sep-06,NKTR-US,International Tower Hill Launches New Corporate Website,INW18-Sep-06,NKTR-US,European Commission Grants Orphan Medicinal Product Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for the Prevention of Pulmonary Fungal Infections in Patients Deemed At Risk,BW14-Sep-06,NKTR-US,Nektar Reports that Pfizer Announced New Analyses Showing that Exubera Is Effective in Diabetes Patients Who Have Respiratory Infections or Who are Exposed to Passive Cigarette Smoke,BW13-Sep-06,NKTR-US,"International Tower Hill Acquires West Tanana Project, Alaska",INW12-Sep-06,NKTR-US,Exubera Hailed as Innovation in Prestigious European and American Awards,BW11-Sep-06,NKTR-US,"Nektar to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medtech Conference, Oppenheimer Diabetes Conference and UBS Investment Bank 2006 Global Life Sciences Conference",BW3-Aug-06,NKTR-US,Nektar Announces Second Quarter 2006 Results,BW26-Jul-06,NKTR-US,Nektar Closes Its Bradford UK Site; Company Focusing on Development of Products Using its Drug Delivery Technology,BW24-Jul-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules BMO Capital Markets Healthcare Conference for 6-December-2006 4:00 PM ET,FCSTEV24-Jul-06,NKTR-US,"Nektar Announces Receipt of $17.6 Million Payment From Affymax, Inc. Under Agreement for Nektar Advanced PEGylation Technology; Cash Payment Resulting From Affymax and Takeda Signing Global Agreement for Hematide(TM) for the Treatment of Anemia",BW22-Jul-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2006 Earnings Release for 2-November-2006 After Market Hours ET,FCSTEV20-Jul-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Cowen & Co. Global Health Care Conference for 7-November-2006 2:40 AM ET,FCSTEV20-Jul-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Oppenheimer Diabetes Investment Conference for 21-September-2006 11:30 AM ET,FCSTEV20-Jul-06,NKTR-US,Nektar Reports That Pfizer to Introduce Exubera in U.S. With a Comprehensive Education Program,BW19-Jul-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2006 Earnings Call for 3-August-2006 5:00 PM ET,FCSTEV19-Jul-06,NKTR-US,Advisory: Nektar Sets Announcement Date and Conference Call for the Second Quarter 2006,BW7-Jul-06,NKTR-US,Nektar and University of Alabama in Huntsville Announce Agreement to Settle Litigation,BW28-Jun-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Windhover Information Euro-Biotech Forum for 28-June-2006 10:10 AM ET,FCSTEV20-Jun-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Drug Information Meeting for 20-June-2006 8:30 AM ET,FCSTEV14-Jun-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Pacific Growth Equities Life Sciences Conference for 14-June-2006 11:30 AM ET,FCSTEV12-Jun-06,NKTR-US,Nektar Reports Pfizer Announcement That New Studies Show More Than Half of Patients at Risk for or Suffering from Complications of Type 2 Diabetes Delay Insulin Injections -- Some More Than Four Years,BW10-Jun-06,NKTR-US,Nektar Reports Pfizer Announcement of New Exubera Data; New Data from Two Large Phase III Trials Reinforce Exubera's Long-Term Efficacy and Safety in Adults with Type 1 or Type 2 Diabetes,BW23-May-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Strategic Research Institute Specialty Pharma Global Summit for 23-May-2006 4:15 PM ET,FCSTEV23-May-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Annual Stockholders Meeting for 1-June-2006 1:00 PM ET,FCSTEV23-May-06,NKTR-US,Advisory: Nektar Therapeutics to Webcast its 2006 Annual Meeting of Stockholders,BW22-May-06,NKTR-US,FDA Grants Fast Track Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for Prevention of Pulmonary Fungal Infections in At-Risk Patients; First Inhaled Anti-Fungal Therapy Under Development for Immunosuppressed Patients,BW13-May-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules TiEcon Conference for 13-May-2006 6:30 PM ET,FCSTEV12-May-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Banc of America Securities Health Care Conference for 16-May-2006 7:40 PM ET,FCSTEV12-May-06,NKTR-US,Bank of America Health Care Conference to Webcast Nektar Corporate Presentation,BW10-May-06,NKTR-US,Nektar Announces First Quarter 2006 Results,BW6-May-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2006 Earnings Release for 3-August-2006,FCSTEV1-May-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2006 Earnings Call for 10-May-2006 5:00 PM ET,FCSTEV1-May-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Morgan Stanley Healthcare Conference for 4-May-2006 2:15 PM ET,FCSTEV1-May-06,NKTR-US,Advisory: Nektar Sets Announcement Date and Conference Call for the First Quarter 2006,BW28-Apr-06,NKTR-US,Morgan Stanley Global Healthcare Unplugged Conference to Webcast Nektar Corporate Presentation,BW28-Apr-06,NKTR-US,"Hot Stocks to Watch for Friday, April 28, 2006: Patent Protection for Core Drug Discovery and Toxicology Platform!",INW27-Apr-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Securities Care Conference for 2-May-2006 2:30 PM ET,FCSTEV27-Apr-06,NKTR-US,Deutsche Bank 31st Annual Health Care Conference to Webcast Nektar Corporate Presentation,BW30-Mar-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules CIBC Biotechnology & Specialty Pharmaceuticals Conference for 5-April-2006 11:30 AM ET,FCSTEV30-Mar-06,NKTR-US,ADVISORY: CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference to Webcast Nektar Corporate Presentation,BW20-Mar-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Bear Biotech West Coast Confab for 23-March-2006 4:30 PM ET,FCSTEV20-Mar-06,NKTR-US,Advisory: Bear Biotech West Coast Confab to Webcast Nektar Corporate Presentation,BW6-Mar-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Lehman Brothers Global Health Care Conference for 9-March-2006 8:30 AM ET,FCSTEV6-Mar-06,NKTR-US,Advisory: Ninth Annual Lehman Brothers Global Healthcare Conference to Webcast Nektar Corporate Presentation,BW3-Mar-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules SG Cowen & Company LLC Health Care Conference for 7-March-2006 1:30 PM ET,FCSTEV3-Mar-06,NKTR-US,2006 SG Cowen & Co. Annual Health Care Conference to Webcast Nektar Corporate Presentation,BW28-Feb-06,NKTR-US,Nektar Announces Financial Results for the Year and Fourth Quarter 2005,BW22-Feb-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2005 Earnings Call for 28-February-2006 5:00 PM ET,FCSTEV21-Feb-06,NKTR-US,Advisory: Nektar Sets Announcement Date and Conference Call for the Year and Fourth Quarter 2005,BW14-Feb-06,NKTR-US,Nektar Announces That U.S. FDA Has Granted Orphan Drug Designation to the First Amphotericin B Inhalation Powder to Prevent Pulmonary Fungal Infections in Immunosuppressed Patients,BW11-Feb-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Securities Small Cap Growth Conference for 16-February-2006 8:00 AM ET,FCSTEV10-Feb-06,NKTR-US,2006 Deutsche Bank Small Cap Growth Conference to Webcast Nektar Corporate Presentation,BW10-Feb-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules BIO CEO & Investor Conference for 15-February-2006 2:00 PM ET,FCSTEV9-Feb-06,NKTR-US,Advisory: BIO CEO and Investor Conference to Webcast Nektar Corporate Presentation,BW7-Feb-06,NKTR-US,Nektar CEO to Retire; Executive Chairman Appointed Acting CEO,BW1-Feb-06,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Merrill Lynch Global Drug Device and Biotechnology Conference for 8-February-2006 9:20 AM ET,FCSTEV1-Feb-06,NKTR-US,Merrill Lynch to Webcast Nektar Corporate Presentation,BW27-Jan-06,NKTR-US,"Pfizer Receives FDA Approval for Exubera, the First Inhaleable Form of Insulin for Controlling Type 1 and Type 2 Diabetes in Adults",BW26-Jan-06,NKTR-US,European Commission Approves Exubera(R) (Inhaled Human Insulin) for Treatment of Type 1 and Type 2 Diabetes,BW19-Jan-06,NKTR-US,Nektar Therapeutics Appoints New Chief Financial Officer,BW12-Jan-06,NKTR-US,Nektar Reports Pfizer to Acquire the Sanofi-Aventis Worldwide Rights to Exubera(R) (Inhaled Human Insulin),BW20-Dec-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules US - Japan Symposium on Drug Delivery Systems for 20-December-2005 1:50 AM ET,FCSTEV6-Dec-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Informed Investors Biotechnology & Healthcare Investor Forum for 7-December-2005 4:25 PM ET,FCSTEV6-Dec-05,NKTR-US,ADVISORY: Nektar Presentation to Be Webcast at Informed Investors Biotechnology & Healthcare Investor Forum,BW11-Nov-05,NKTR-US,Advisory: Lehman Brothers to Webcast Nektar's Corporate Presentation,BW11-Nov-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Lehman Brothers Small Cap Conference for 18-November-2005 11:40 AM ET,FCSTEV8-Nov-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules BIO-Europe Partnering Conference for 8-November-2005 11:00 AM ET,FCSTEV7-Nov-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules S.G. Cowan and Co. Global Healthcare Conference for 9-November-2005 7:55 AM ET,FCSTEV7-Nov-05,NKTR-US,Advisory: SG Cowen & Co. to Webcast Nektar's Corporate Presentation,BW3-Nov-05,NKTR-US,Nektar Announces Third Quarter 2005 Financial Results,BW1-Nov-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules CIBC Healthcare Conference for 7-November-2005 2:30 PM ET,FCSTEV31-Oct-05,NKTR-US,CIBC World Markets to Webcast Nektar's Corporate Presentation,BW28-Oct-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2005 Earnings Call for 3-November-2005 5:00 PM ET,FCSTEV28-Oct-05,NKTR-US,Advisory: Nektar Sets Announcement Date and Conference Call for Third Quarter 2005 Results,BW28-Oct-05,NKTR-US,Nektar Reports on Pfizer and Sanofi-Aventis Statement on Status of Exubera,BW20-Oct-05,NKTR-US,Nektar Announces Closing of Aerogen Acquisition,BW14-Oct-05,NKTR-US,"MORNING UPDATE: Seven Summits Research issues alerts for UNH, NTAP, FDC, NKTR, and PGR...",PRN13-Oct-05,NKTR-US,Nektar Therapeutics Reports Exubera(R) Receives Positive Opinion from CHMP for the Treatment of Type 1 and Type 2 Diabetes,BW5-Oct-05,NKTR-US,"Chiron and Nektar Announce Initiation of Phase III Clinical Program Evaluating Tobramycin Inhalation Powder in Cystic Fibrosis Patients -- First of Two Pivotal Trials Begins, Second Planned for 2006<>Pocket-size TIP inhaler, with drug capsules (Photo: Business Wire)<>Pocket-size TIP inhaler (Photo: Business Wire)",BW1-Oct-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2006 Earnings Release for 10-May-2006,FCSTEV29-Sep-05,NKTR-US,Nektar Announces Inhaled Amphotericin B Product in Human Clinical Trials for Preventing Fatal Pulmonary Fungal Infections in Immunosuppressed Patients<>Nektar Therapeutics' inhaled amphotericin B product for preventing fatal pulmonary fungal infections in immunosuppressed patients is delivered in a pocket size inhaler. (Photo: Business Wire),BW29-Sep-05,NKTR-US,Nektar Announces Inhaled Antibiotics Product to Prevent Pneumonia in Mechanically-Ventilated Patients,BW29-Sep-05,NKTR-US,Baxter Announces Collaborations to Develop Longer Acting Forms of Blood Clotting Factors,PRN29-Sep-05,NKTR-US,Nektar and Baxter Collaborate to Develop Novel Longer-Acting Forms of Blood Clotting Factors,BW27-Sep-05,NKTR-US,Nektar Announces Exercise of Option to Purchase $40 Million of Convertible Subordinated Notes,BW26-Sep-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Investor Day for 29-September-2005 11:00 AM ET,FCSTEV26-Sep-05,NKTR-US,"Nektar to Webcast Investor Day Presentations on September 29, 2005",BW22-Sep-05,NKTR-US,Nektar Therapeutics Announces Private Offering of Convertible Subordinated Notes,BW21-Sep-05,NKTR-US,Nektar Therapeutics Announces Proposed Issuance of Convertible Subordinated Notes,BW20-Sep-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules UBS Warburg Life Sciences Conference for 28-September-2005 8:30 AM ET,FCSTEV14-Sep-05,NKTR-US,"Nektar Therapeutics(NKTR-US) Schedules Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference for 16-September-2005 10:00 AM ET",FCSTEV13-Sep-05,NKTR-US,Advisory: Merrill Lynch to Webcast Nektar's Corporate Presentation,BW12-Sep-05,NKTR-US,"MORNING UPDATE: Seven Summits Research issues alerts for RFMD, NKTR, RMBS, ATVI, and BA",PRN8-Sep-05,NKTR-US,Nektar Announces Investor's Election to Acquire $8M of Nektar's Common Stock,BW8-Sep-05,NKTR-US,Nektar Reports That FDA Advisory Committee Recommends Approval of Exubera(R) for Use in Adults with Type 1 and Type 2 Diabetes,BW8-Sep-05,NKTR-US,Nektar Reports That Nasdaq Halted Trading of Nektar Common Stock Today; FDA Advisory Committee Meeting to Discuss Exubera(R) (Insulin (rDNA Origin) Powder for Oral Inhalation),BW6-Sep-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules ThinkEquity Growth Conference for 12-September-2005 4:30 PM ET,FCSTEV2-Sep-05,NKTR-US,Advisory: ThinkEquity Partners LLC to Webcast Nektar's Corporate Presentation,BW23-Aug-05,NKTR-US,Nektar Therapeutics Selects MetricStream,INW17-Aug-05,NKTR-US,Nektar Closes $24 Million Common Stock Financing: Elects to Pay All Cash for Aerogen Acquisition,BW16-Aug-05,NKTR-US,Nektar Announces $24 Million Common Stock Financing,BW15-Aug-05,NKTR-US,Nektar to Acquire Aerogen to Broaden Pulmonary Technology Base and Strengthen Capabilities for Treatment in the Acute Care Setting,BW4-Aug-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2005 Earnings Call for 4-August-2005 5:00 PM ET,FCSTEV4-Aug-05,NKTR-US,Nektar Announces Second Quarter 2005 Results,BW28-Jul-05,NKTR-US,Advisory: Nektar Sets Announcement Date and Conference Call for Second Quarter 2005 Results,BW28-Jul-05,NKTR-US,Banc of America Securities to Webcast Nektar's Corporate Presentation,BW26-Jul-05,NKTR-US,Nektar Announces Newly-Created Diabetes Group and General Manager,BW21-Jul-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Banc of America Securities Specialty Pharmaceuticals Conference for 28-July-2005 12:45 PM ET,FCSTEV21-Jul-05,NKTR-US,Banc of America Securities to Webcast Nektar's Corporate Presentation,BW11-Jul-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2005 Earnings Release for 28-February-2006,FCSTEV11-Jul-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2005 Earnings Release for 3-November-2005,FCSTEV11-Jul-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2005 Earnings Release for 4-August-2005,FCSTEV20-Jun-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules BIO International Convention for 20-June-2005 2:45 PM ET,FCSTEV14-Jun-05,NKTR-US,Nektar Reports that Pfizer Inc and sanofi-aventis Announce Data Presented at American Diabetes Association Scientific Sessions Support Exubera Efficacy and Safety Profile in Type 1 and Type 2 Diabetes,BW6-Jun-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Pacific Growth Equities Life Sciences Growth Investor Conference for 6-June-2005 12:30 PM ET,FCSTEV2-Jun-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Annual Stockholders Meeting for 2-June-2005 1:00 PM ET,FCSTEV2-Jun-05,NKTR-US,Advisory: Nektar Therapeutics to Webcast its 2005 Annual Meeting of Stockholders,BW31-May-05,NKTR-US,Advisory: Pacific Growth Equities to Webcast Nektar's Corporate Presentation,BW24-May-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules UBS Global Specialty Pharmaceuticals Conference for 24-May-2005 4:00 PM ET,FCSTEV18-May-05,NKTR-US,Advisory: UBS Investment Bank to Webcast Nektar's Corporate Presentation,BW18-May-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Banc of America Health Care Conference for 18-May-2005 5:00 PM ET,FCSTEV12-May-05,NKTR-US,Advisory: Banc of America Securities to Webcast Nektar's Corporate Presentation,BW9-May-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2005 Earnings Call for 9-May-2005 5:00 PM ET,FCSTEV9-May-05,NKTR-US,Nektar Announces Appointment of Joseph Krivulka to its Board of Directors,BW9-May-05,NKTR-US,Nektar Announces First Quarter 2005 Results,BW8-May-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2005 Earnings Release for 9-May-2005,FCSTEV5-May-05,NKTR-US,Advisory: Nektar Sets Date and Conference Call for First Quarter 2005 Results,BW4-May-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Deutsche Bank Securities Health Care Conference for 4-May-2005 10:00 AM ET,FCSTEV28-Apr-05,NKTR-US,Advisory: Deutsche Bank to Webcast Nektar's Corporate Presentation,BW31-Mar-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Lehman Global Health Care Conference for 31-March-2005 11:15 AM ET,FCSTEV24-Mar-05,NKTR-US,Advisory: Lehman Brothers to Webcast Nektar's Corporate Presentation,BW16-Mar-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Cowen Health Care Conference for 16-March-2005 1:30 PM ET,FCSTEV10-Mar-05,NKTR-US,Advisory: SG Cowen to Webcast Nektar's Corporate Presentation,BW4-Mar-05,NKTR-US,"MORNING UPDATE: Man Securities Inc. Issues Alerts for DELL, AW, KSS, NKTR, and TTWO",PRN2-Mar-05,NKTR-US,Nektar Reports that Pfizer and The Sanofi-Aventis Group Seek Approval to Market Exubera in the United States,BW1-Mar-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2004 Earnings Call for 1-March-2005 5:00 PM ET,FCSTEV1-Mar-05,NKTR-US,Nektar Announces Financial Results for the Year and Fourth Quarter 2004,BW1-Mar-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Wells Fargo Health Care Conference for 1-March-2005 2:00 PM ET,FCSTEV1-Mar-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Suntrust Robinson Humphrey Conference for 1-March-2005 10:20 AM ET,FCSTEV28-Feb-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2004 Earnings Release for 1-March-2005,FCSTEV23-Feb-05,NKTR-US,Leerink Swann/MEDACorp to Webcast Nektar's Corporate Presentation,BW23-Feb-05,NKTR-US,Advisory: SunTrust Robinson Humphrey to Webcast Nektar's Question and Answer Session,BW23-Feb-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules BIO CEO & Investor Conference for 23-February-2005 3:00 PM ET,FCSTEV23-Feb-05,NKTR-US,Advisory: Nektar Sets Date and Conference Call for Year and Fourth Quarter 2004 Results,BW17-Feb-05,NKTR-US,BIO CEO & Investor Conference to Webcast Nektar's Corporate Presentation,BW9-Feb-05,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Merrill Lynch Global Pharmaceutical Biotechnology and Medical Device Conference for 9-February-2005 3:00 PM ET,FCSTEV1-Feb-05,NKTR-US,"Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Nektar's Corporate Presentation",BW25-Jan-05,NKTR-US,Bayer HealthCare and Nektar Therapeutics Collaborate to Develop Inhaleable Ciprofloxacin Therapy for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients,BW24-Jan-05,NKTR-US,Nektar and Zelos Announce Collaboration to Develop Inhaled Parathyroid Hormone Therapy for Osteoporosis,BW17-Dec-04,NKTR-US,Sixth Product Using Nektar Technology Approved in the U.S.,BW7-Dec-04,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Informed Investors Biotechnology & Healthcare Forum for 7-December-2004 4:00 PM ET,FCSTEV2-Dec-04,NKTR-US,"MORNING UPDATE: Man Securities issues alerts for RFMD, UTSI, SYMC, NKTR, and CI",PRN1-Dec-04,NKTR-US,"Forum Alert: Nektar Therapeutics Presentation at Informed Investors Biotechnology & Healthcare Stocks Forum at the Crowne Plaza in Foster City on Dec. 7, 2004, 1:00 pm PT",BW1-Dec-04,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules The Lazard Life Sciences Conference for 1-December-2004 8:30 AM ET,FCSTEV1-Dec-04,NKTR-US,"Market Pulse Breaking News Alert for Wednesday, December 1, 2004: PKCY - Park City Group Targets Multi-Billion Dollar Asian Market With High Profile Customers and Patented Language Support Capability!",INW22-Nov-04,NKTR-US,Lazard Life Sciences Conference to Webcast Nektar's Corporate Presentation,BW16-Nov-04,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules SG Cowen Healthcare Conference for 17-November-2004 2:35 AM ET,FCSTEV11-Nov-04,NKTR-US,SG Cowen 5th Annual Global Health Care Conference to Webcast Nektar's Corporate Presentation,BW8-Nov-04,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules CIBC World Markets Health Care Conference for 8-November-2004 4:00 PM ET,FCSTEV3-Nov-04,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2004 Earnings Call for 3-November-2004 5:00 PM ET,FCSTEV3-Nov-04,NKTR-US,Nektar Announces Third Quarter 2004 Financial Results,BW2-Nov-04,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2004 Earnings Release for 3-November-2004,FCSTEV2-Nov-04,NKTR-US,CIBC World Markets Fifteenth Annual Healthcare Conference to Webcast Nektar Presentation,BW20-Oct-04,NKTR-US,ADVISORY: Nektar Sets Date and Conference Call for Third Quarter 2004 Results,BW14-Oct-04,NKTR-US,Chiron Presents Data on Tobramycin Powder for Inhalation at North American Cystic Fibrosis Conference,BW27-Sep-04,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules UBS Global Life Science Conference for 27-September-2004 11:30 AM ET,FCSTEV23-Sep-04,NKTR-US,"Nektar Therapeutics(NKTR-US) Schedules Merrill Lynch Global Drug, Biotech and Medical Devices Conference for 23-September-2004 12:00 PM ET",FCSTEV22-Sep-04,NKTR-US,UBS Global Life Sciences Conference to Webcast Nektar Presentation,BW21-Sep-04,NKTR-US,"Merrill Lynch Global Drug, Biotech and Medical Devices Conference to Webcast Nektar Presentation",BW20-Sep-04,NKTR-US,"Nektar Reports That Pfizer and Eyetech Provide Regulatory Update on Macugen -- pegaptanib sodium injection; EU Filing Accepted, Filing in Canada Completed and Japanese Trial Underway",BW9-Sep-04,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules BioCentury's NewsMakers in the Biotech Industry Investment Conference for 9-September-2004 4:30 PM ET,FCSTEV7-Sep-04,NKTR-US,"Law Offices Of Charles J. Piven, P.A. Announces Class Action Lawsuit Against Nektar Therapeutics -- NKTR",PMZ7-Sep-04,NKTR-US,"Schatz & Nobel, P.C. Announces Class Action Lawsuit Against Nektar Therapeutics",PRN7-Sep-04,NKTR-US,Nektar Reports that New Data on Exubera Showed Sustained Blood Glucose Control and Pulmonary Function in Patients With Type 2 Diabetes,BW3-Sep-04,NKTR-US,"Shareholder Class Action Filed Against Nektar Therapeutics by the Law Firm of Schiffrin & Barroway, LLP",PRN2-Sep-04,NKTR-US,NewsMakers in the Biotech Industry Investment Conference to Webcast Nektar Corporate Presentation,BW27-Aug-04,NKTR-US,Nektar Reports that FDA Advisory Committee Reviews Clinical Data of Eyetech/Pfizer Priority 1 NDA Submission for Macugen,BW2-Aug-04,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2004 Earnings Call for 2-August-2004 5:00 PM ET,FCSTEV2-Aug-04,NKTR-US,Nektar Announces Agreement with Pfizer to Use Nektar PEGylation Technology,BW2-Aug-04,NKTR-US,Nektar Announces Second Quarter 2004 Results,BW1-Aug-04,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2004 Earnings Release for 2-August-2004,FCSTEV29-Jul-04,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules KBW Community Bank Investor Conference for 29-July-2004 2:15 PM ET,FCSTEV22-Jul-04,NKTR-US,Banc of America Securities 2004 Specialty Pharmaceuticals Conference to Webcast Nektar's Presentation,BW19-Jul-04,NKTR-US,Nektar Sets Date and Conference Call for Second Quarter 2004 Results,BW14-Jun-04,NKTR-US,Nektar Therapeutics to Webcast Its Annual Stockholders Meeting,BW8-Jun-04,NKTR-US,Pacific Growth Equities Life Sciences Growth Conference to Webcast Nektar's Presentation,BW7-Jun-04,NKTR-US,Nektar Reports That New Long-Term Safety and Efficacy Data on EXUBERA --Human Insulin Powder-- Presented at American Diabetes Association Scientific Sessions,BW28-May-04,NKTR-US,Friedman Billings Ramsey to Webcast Nektar Presentation at 8th Annual Growth Investor Conference,BW20-May-04,NKTR-US,UBS 2004 Global Specialty Pharmaceuticals Conference to Webcast Nektar's Presentation,BW14-May-04,NKTR-US,Banc of America Securities 2004 Health Care Conference to Webcast Nektar's Presentation,BW7-May-04,NKTR-US,Advisory: SunTrust to Webcast Nektar Corporate Update at Therapeutics Conference,BW5-May-04,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q1 2004 Earnings Call for 5-May-2004 5:00 PM ET,FCSTEV5-May-04,NKTR-US,Nektar Announces Agreements with GlaxoSmithKline and Undisclosed Biotechnology Company,BW5-May-04,NKTR-US,Nektar Announces First Quarter 2004 Results,BW28-Apr-04,NKTR-US,Deutsche Bank Securities 2004 Health Care Conference to Webcast Nektar's Presentation,BW21-Apr-04,NKTR-US,ADVISORY: Nektar Sets Date and Conference Call for First Quarter 2004,BW13-Apr-04,NKTR-US,"Nektar Revises Accounting Treatment of Convertible Note Exchange Transactions; No Impact on Cash, Revenue, Operating Expenses, or Operating Loss",BW1-Apr-04,NKTR-US,Nektar Therapeutics Announces Details of Redemption of 6 3/4% Convertible Subordinated Debentures Due October 2006,BW30-Mar-04,NKTR-US,Nektar Therapeutics Announces Completion of Redemption of 3% Convertible Subordinated Notes Due June 2010,BW9-Mar-04,NKTR-US,Nektar Therapeutics Announces Details of Redemption of 3% Convertible Subordinated Notes due June 2010,BW8-Mar-04,NKTR-US,Nektar Therapeutics Announces Intention to Redeem 3% Convertible Subordinated Notes Due June 2010,BW8-Mar-04,NKTR-US,Nektar Therapeutics Announces Common Stock Public Offering,BW8-Mar-04,NKTR-US,"MORNING UPDATE: Man Securities Issues Alerts for AMAT, MCD, MER, NKTR, and PHM",PRN4-Mar-04,NKTR-US,Nektar Reports that Pfizer and Aventis Seek Approval to Market Exubera in Europe,BW3-Mar-04,NKTR-US,SG Cowen 24th Annual Health Care Conference to Webcast Nektar's Corporate Presentation,BW27-Feb-04,NKTR-US,Lehman Brothers Seventh Annual Global Healthcare Conference to Webcast Nektar's Corporate Presentation,BW20-Feb-04,NKTR-US,CORRECTING and REPLACING BIO CEO & Investor Conference to Webcast Nektar's Corporate Presentation,BW2-Feb-04,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q4 2003 Earnings Call for 2-February-2004 5:00 PM ET,FCSTEV2-Feb-04,NKTR-US,Nektar Announces Financial Results for the Year and Fourth Quarter 2003,BW2-Feb-04,NKTR-US,Nektar Discloses Collaboration with Roche for CERA,BW28-Jan-04,NKTR-US,"Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Nektar's Corporate Presentation",BW21-Jan-04,NKTR-US,ADVISORY: Nektar Sets Date and Conference Call for Year and Fourth Quarter 2003,BW6-Jan-04,NKTR-US,Nektar Announces Appointment of Susan Wang to its Board of Directors,BW6-Nov-03,NKTR-US,CIBC Annual Healthcare Conference to Webcast Nektar's Corporate Presentation,BW5-Nov-03,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q3 2003 Earnings Call for 5-November-2003 5:00 PM ET,FCSTEV5-Nov-03,NKTR-US,Nektar Announces Third Quarter 2003 Results,BW27-Oct-03,NKTR-US,Data Presented by Nektar Therapeutics Show Broad Applications for Its Drug Delivery Technologies,BW23-Oct-03,NKTR-US,Nektar Sets Date and Conference Call for Third Quarter 2003 Financial Results,BW16-Sep-03,NKTR-US,UBS GLOBAL LIFE SCIENCES CONFERENCE TO WEBCAST NEKTAR'S CORPORATE PRESENTATION,BW6-Aug-03,NKTR-US,Nektar Therapeutics(NKTR-US) Schedules Q2 2003 Earnings Call for 6-August-2003 5:00 PM ET,FCSTEV6-Aug-03,NKTR-US,NEKTAR ANNOUNCES SECOND QUARTER 2003 RESULTS,BW30-Jul-03,NKTR-US,NEKTAR ANNOUNCES EXERCISE OF OPTION TO PURCHASE $10 MILLION OF CONVERTIBLE SUBORDINATED NOTES,BW22-Jul-03,NKTR-US,NEKTAR SETS DATE AND CONFERENCE CALL FOR SECOND QUARTER 2003 FINANCIAL RESULTS,BW1-Jul-03,NKTR-US,GENETIC ENGINEERING NEWS REPORTS ADVANCES IN DRUG DELIVERY TECHNOLOGIES,BW25-Jun-03,NKTR-US,NEKTAR THERAPEUTICS ANNOUNCES OFFERING OF CONVERTIBLE SUBORDINATED NOTES,BW23-Jun-03,NKTR-US,NEKTAR THERAPEUTICS ANNOUNCES PROPOSED ISSUANCE OF CONVERTIBLE SUBORDINATED NOTES,BW16-Jun-03,NKTR-US,NEKTAR REPORTS ON PHASE III EXUBERA DATA THAT SHOW BETTER GLYCEMIC CONTROL COMPARED WITH ROSIGLITAZONE IN TYPE 2 DIABETES PATIENTS,BW3-Jun-03,NKTR-US,NEKTAR THERAPEUTICS TO WEBCAST ITS ANNUAL STOCKHOLDERS MEETING,BW30-May-03,NKTR-US,UBS WARBURG GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE TO WEBCAST NEKTAR'S CORPORATE PRESENTATION,BW22-May-03,NKTR-US,FRIEDMAN BILLINGS RAMSEY 7TH ANNUAL TECHNOLOGY AND GROWTH INVESTOR CONFERENCE TO WEBCAST NEKTAR'S CORPORATE PRESENTATION,BW15-May-03,NKTR-US,CDI Innovantage Wins Contract With Nektar,PRN13-May-03,NKTR-US,ENZON PHARMACEUTICALS REPORTS THIRD QUARTER FINANCIAL RESULTS; TOTAL REVENUES INCREASE BY 118% AND PHASE II CLINICAL TRIALS INITIATED FOR PROTHECAN IN GASTRIC CANCER,BW30-Apr-03,NKTR-US,DEUTSCHE BANK 28TH ANNUAL HEALTH CARE CONFERENCE TO WEBCAST NEKTAR'S CORPORATE PRESENTATION,BW22-Apr-03,NKTR-US,NETKAR ANNOUNCES FIRST QUARTER 2003 RESULTS,BW15-Apr-03,NKTR-US,NEKTAR SETS DATE AND CONFERENCE CALL FOR FIRST QUARTER 2003 FINANCIAL RESULTS,BW27-Mar-03,NKTR-US,FIFTH PRODUCT USING NEKTAR TECHNOLOGY APPROVED IN U.S.; FDA APPROVES PHARMACIA CORPORATION'S SOMAVERT FOR THE TREATMENT OF ACROMEGALY,BW14-Mar-03,NKTR-US,SG COWEN ANNUAL HEALTHCARE CONFERENCE TO WEBCAST NEKTAR'S CORPORATE PRESENTATION,BW3-Mar-03,NKTR-US,NEKTAR CREATES NEW EXECUTIVE POSITION AND ADDS TO MANAGEMENT TEAM TO LEAD COMPANY TO FURTHER GROWTH AND TOWARD PROFITABILITY,BW28-Feb-03,NKTR-US,LEHMAN BROTHERS TO WEBCAST NEKTAR'S CORPORATE PRESENTATION,BW19-Feb-03,NKTR-US,BIO CEO & INVESTOR CONFERENCE TO WEBCAST NEKTAR'S CORPORATE PRESENTATION,BW18-Feb-03,NKTR-US,"ENZON FILES FORM 10-Q FOR QUARTER ENDED DECEMBER 31, 2002; REFLECTS NON-CASH REVISION TO SECOND QUARTER FINANCIAL RESULTS",BW31-Jan-03,NKTR-US,"MERRILL LYNCH GLOBAL PHARMACEUTICAL, BIOTECHNOLOGY AND MEDICAL DEVICE CONFERENCE TO WEBCAST NEKTAR'S CORPORATE PRESENTATION",BW28-Jan-03,NKTR-US,NEKTAR ANNOUNCES FOURTH QUARTER AND YEAR ENDED 2002 FINANCIAL RESULTS,BW23-Jan-03,NKTR-US,"NEKTAR THERAPEUTICS AND  THE STRAUMANN GROUP ANNOUNCE LICENSE, MANUFACTURING AND SUPPLY  AGREEMENT FOR DENTAL APPLICATIONS",BW21-Jan-03,NKTR-US,ADVISORY/NEKTAR SETS DATE AND CONFERENCE CALL FOR FOURTH QUARTER AND YEAR ENDED 2002 FINANCIAL RESULTS,BW15-Jan-03,NKTR-US,INHALE BECOMES NEKTAR THERAPEUTICS REFLECTING BROADENED CAPABILITIES AND EXPANDED APPROACH TO DRUG DELIVERY,BW